PrECOG Protocol Number: PrE0 405 
Date: 10/11/2021 
 
 
 
PrECOG Protocol Number: PrE0405 
Phase II Study of Bendamustine and Rituximab plus 
Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years 
of Age  
 
 
 
 
 
 NCT#:  [STUDY_ID_REMOVED]  
IND #:  
 143290  
Protocol Version Number: 
 5.0 
Version Date:  
 10/11 /2021 
 

PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/11/2021 
 
 
 
PrECOG Protocol Number: PrE0405  
Phase II Study of Bendamustine and Rituximab plus 
Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years 
of Age 
STUDY CHAIR:  Craig A. Portell, MD  
STUDY CO -CHAIR:   
:  
STATISTICIAN:   
PRECOG STUDY SITE CO NTACT:   
MEDICAL MONITOR:   
(Internal Use Only) Genentech  US Ref. ID Number : ML40551  
 
 
 
 
 
   
IND #:  
 143290  
Version Number: 
 5.0 
Version Date:  
 October  11, 2021 
  
Release/Revision History  
Version 1.0 : 4/9/2019 Released to Sites  
Version 2.0: 8/30 /2019  Released to Sites  
Version 3.0: 1/29/2020  Released to Sites  
Version 4.0:  11/9/2020  Released to Sites  
Version 5.0: 10/11/2021  Released to Sites  
 
This protocol contains information that is confidential and proprietary  

PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
2 Table of Contents  
List of Abbreviations  ....................................................................................................................................6  
1. Introduction- Background and Rationale  ...........................................................................................9  
1.1 Mantle Cell Lymphoma – Disease Overview  ................................................................................9  
1.2 Induction Therapy in MCL  .............................................................................................................9  
1.3 Pending Studies with Bendamustine and Rituximab in MCL  ..................................................... 10 
1.4 Venetoclax (ABT -199, GDC -0199)  ............................................................................................ 10 
1.5 MRD Monitoring in MCL  ............................................................................................................. 11  
1.6 Summary of Rationale for Proposed Study  ............................................................................... 11 
2. Study Objectives  ................................................................................................................................ 13 
2.1 Primary Objective  ....................................................................................................................... 13 
2.2 Secondary Objectives  ................................................................................................................ 13  
2.3 Exploratory Objectives  ............................................................................................................... 13  
3. Selection of Patients  .......................................................................................................................... 14 
4. Registration Procedures  .................................................................................................................... 17 
4.1 Ethics  ......................................................................................................................................... 17 
4.2 Regulatory Requirements  .......................................................................................................... 17  
4.3 Patient Registration  .................................................................................................................... 17 
4.4 Research Tissue, Bone Marrow and Blood Samples  ................................................................ 17 
5. Treatment Plan  ................................................................................................................................... 19 
5.1 Overview  .................................................................................................................................... 19 
5.2 Treatment and Administration Schedule  .................................................................................... 20 
5.3 Tumor Lysis Prophylaxis  ............................................................................................................ 21  
5.4 Tumor Lysis Monitoring  .............................................................................................................. 22  
5.5 Neutropenic Sepsis Prophy laxis ................................................................................................ 23 
5.6 Infection Prophylaxis  .................................................................................................................. 23  
5.7 Monitoring for Cytomegalovirus (CMV)  ...................................................................................... 23 
6. Dose Delays & Modifications  ............................................................................................................ 25  
6.1 Dose Modifications  ..................................................................................................................... 25 
6.2 Concurrent Therapies  ................................................................................................................ 28  
7. Study Duration and Discontinuation of Therapy  ............................................................................ 31 
7.1 Study Duration  ........................................................................................................................... 31 
7.2 Duration of Follow -Up ................................................................................................................ 31  
7.3 Criteria for Removal from Study Treatment  ............................................................................... 31 
8. Adverse Event Reporting  .................................................................................................................. 33  
8.1 Collection of Safety Information  ................................................................................................. 33 
8.2 Serious Adverse Events  ............................................................................................................. 34  
8.3 Adverse Events of Special  Interest (AESI)  ................................................................................ 35 
8.4 Special Situation Reports ........................................................................................................... 36  
8.5 SAE Reporting Requirements  .................................................................................................... 36 
8.6 Product Complaints  .................................................................................................................... 37 
8.7 Reporting of Other Second Primary Cancers  ............................................................................ 38 
8.8 Procedures in Case of Pregnancy  ............................................................................................. 38 
9. Measurement of Effect  ....................................................................................................................... 39 
9.1 Response Assessments  ............................................................................................................ 39  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
3 9.2 Lymphoma Response Criteria (Lugano Classification)32 ........................................................... 39 
9.3 Minimum Residual Disease (MRD) Measurements  ................................................................... 40 
10. Study Treatments, Parameters, and Assessments  ........................................................................ 41 
11. Drug Formulation and Procurement  ................................................................................................ 46 
11.1  Venetoclax21,22 ........................................................................................................................... 46 
11.2  Bendamustine38 ......................................................................................................................... 49 
11.3  Rituximab39,40 ............................................................................................................................. 51 
12. Statistical Considerations  ................................................................................................................. 54  
12.1  Study Design, Sample Size Considerations & Statistical Analyses  .......................................... 54 
12.2  Planned Analyses  ...................................................................................................................... 54 
13. Laboratory and Pathology Correlative Studies  ............................................................................... 57 
13.1  Correlative Studies: Mandatory Tumor Samples (if sufficient tissue available)  ......................... 57 
13.2  Correlative Studies: Mandatory Bone Marrow Samples  ............................................................ 58 
13.3  Correlative Studies: Mandatory and Optional Peripheral Blood Samples  ................................. 59 
13.4  Assay Methodology  .................................................................................................................... 61 
14. Administrative  .................................................................................................................................... 62 
14.1  Protocol Compliance  .................................................................................................................. 62  
14.2  Institutional Review Board ......................................................................................................... 62 
14.3  Informed Consent Procedures  ................................................................................................... 62 
14.4  Safety Communication  ............................................................................................................... 63  
14.5  Monitoring  63 
14.6  Study Records  ........................................................................................................................... 63 
14.7  Electronic Case Report Form (eCRF) Information  .................................................................... 64 
14.8  Records Retention  ..................................................................................................................... 64 
15. References  .......................................................................................................................................... 65 
Appendix I:  ECOG Performance Status ................................................................................. 68 
Appendix II:  Calculation of Creatinine Clearance Using the Cockcroft- Gault Formula  ..... 69 
Appendix III:  Additional Excluded and Cautionary Medications  ........................................... 70 
Appendix IV:  Definitions for Tumor Lysis Syndrome31 ........................................................... 72 
Appendix V:  Revised Criteria for Response Assessment32 ................................................... 73 
Appendix VI:  Investigator’s Statement  ..................................................................................... 76 
 
  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
4 PrECOG STUDY SITE CON TACT  MEDICAL MONITOR  
 
Projec
t Manager  
PrECOG, LLC  
1818 Market Street  
Suite 3000  
Philadelphia, PA 19103  
Phone: 215- 789-7001  
Email: PrE0405 @precogllc.org   
985 Old Eagle School Road 
Suite 510  
Wayne, PA 19087  
During normal business hours  
(8:30 am -5:00 pm EST):  
Phone: 610- 354-0404  
After normal business hours:  
Phone: 484- 574-2367  
Email:   
SAE Email : PrE0405SAE@qdservices.com  
 

PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
5 Brief Protocol Synopsis 
See Protocol Document Sections for complete details  
Study Schema  
 
Mantle Cell Lymphoma (MCL)  
 
 
 INDUCTION1     MAINTENANCE5 
    
 
     
 
   
Accrual goal: 33 patients  
Cycle length: 28 days (4 weeks)  
1 Interim safety analysis planned after 19 patients are enrolled for review of tumor lysis syndrome ( TLS) events . Section 
12.2. 1 for details.  
2 If the first two cycles of intravenous (IV) rituximab (or two consecutive cycles)  are well tolerated, IV rituximab may be 
replaced with 1400 mg/23,400 units subcutaneous ( SQ) ri tuximab/hyaluronic acid on Day 1 of Cycles 3 -6 (or after 2 
consecutive cycles are well tolerated). See Section 5.2.3 for details.  
3 Per investigator discretion, bendamustine may be started at 70 mg/m2 in patients over the age of 75 years with 
comorbid conditions or patients over the age of 80 years without comorbid conditions.  See Section 5.2.2 for details.  
4 Cycle 1 : Goal venetoclax dose will be 400 mg but careful titration and escalation of dose will  need to be done during 
Cycle 1 to mitigate the risk of TLS . See Section 5.3  and Section 5.4 for details.  
5 After 6 cycles of venetoclax, bendamustine and rituximab, subjects responding to therapy may receive maintenance 
rituximab (one dose every 8 ± 2 weeks for 12 doses or 24 months whichever comes first) per physician and patient 
preference.  
NOTE:  At the time of restaging (or if a scan is done earlier for another reason) and disease progression is noted , 
patients will come off study.  R 
E 
G 
I 
S 
T 
R 
A 
T 
I 
O 
N Rituximab  375 mg/m2 IV day 1 
every 28 days x 6 cycles2 
Bendamustine 90 mg/m2 IV days 
1, 2 every  28 days x 6 cycles3 
Cycle 1: Venetoclax titration to 
200 mg PO daily days 1-284 
Cycle 2-6: Venetoclax 400 mg PO 
daily days 1 -10 of each 28 day 
cycle  Per Investigator 
Discretion  Rituximab 375 mg/m2 IV or 
SQ every 8 weeks x 12 
doses or 24 month s2 
(whichever comes first)  
Progression  
Off Study  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
6 List of Abbreviations 
5-HT3 5-Hydroxytryptamine 3 Serotonin R eceptor  
5PS 5 Point Scale  
AE Adverse E vent 
AESI  Adverse Events of Special Interest  
ALC Absolute Lymphocyte Count  
ALT Alanine A minotransferase  
ANC  Absolute Neutrophil C ount 
anti-HBc or HBcAB  Hepatitis B Core Antibody  
AST Aspartate A minotransferase  
BCL1  B-Cell Lymphoma 1  
BCL2  B-Cell Lymphoma 2  
BR Bendamustine Rituximab  
BSA Body Surface A rea 
BUN  Blood Urea Nitrogen  
C Celsius  
CBC  Complete Blood Count  
CBPF  Central Biorepository Pathology Facility  
CLL Chronic Lymphocytic Leukemia  
cm Centimeter  
CMV  Cytomegalovirus  
CNS  Central Nervous System  
CI Confidence Interval  
CR Complete Response or Complete Remission  
CrCl Creatinine Clearance  
CT Computerized Tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
CTEP  Cancer Therapeutic Evaluation Program  
dL Deciliter  
DNA  Deoxyribonucleic A cid 
DSMB  Data Safety Monitoring Board  
ECOG  Eastern Cooperative Oncology Group  
ECOG -ACRIN  Eastern Cooperative Oncology Group -American College of Radiology 
Imaging Network  
eCRF  electronic Case Report Form  
eDC Electro nic Data C apture  
EDTA  Ethylenediamine  Tetraaceti c Acid 
F Fahrenheit  
FDA Food and Drug Administration  
FDG  Fluorodeoxyglucose  
FFPE  Formalin -Fixed Paraffin -Embedded  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
7 FISH  Fluorescence In Situ H ybridization  
FR Fludarabine and Rituximab  
g gram  
GCP  Good Clinical Practice  
GCSF  Granulocyte Colony -Stimulating Factor  
GI Gastrointestinal  
HBsAg  Hepatitis B Surface A ntigen  
HBV Hepatitis B Virus  
HCO 3 Bicarbonate  
Hct Hematocrit  
HCV  Hepatitis C Virus  
Hgb Hemoglobin  
HIPPA  Health Information Portability and Accountability Act  
HIV Human Immunodeficiency Virus  
hr Hour  
HR Hazard Ratio  
HSV Herpes Simplex Virus  
IB Investigator Brochure  
ICH International Conference on Harmonisation  
ICF Informed Consent Form  
IHC Immunohistochemistry  
IND Investigational New Drug  
IRB Institutional R eview Board 
IV Intravenous  
kg Kilogram  
LDH Lactate Dehydrogenase  
LDi Longest Transverse Diameter of a Lesion  
m Meter  
m2 Meter Squared  
mcg Microgram  
MCL  Mantle Cell Lymphoma  
mg Milligram  
min Minute  
MIPI MCL International Prognostic  Index  
mL Milliliter  
mm Millimeter  
mm3 Cubic Millimeter  
mmol  Millimole  
MRD  Minimal Residual Disease  
MRI Magnetic Resonance I maging  
n number  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
8 NCCN  National Comprehensive Cancer Network  
NCI National Cancer Institute  
NCI CTCAE  National Cancer Institute Common Terminology Criteria for Adverse 
Events  
NGS  Next Generation Sequencing  
NHL Non-Hodgkin Lymphoma  
OBI On Body I njector  
ORR  Overall Response Rate  
OS Overall Survival  
PBMC  Peripheral Blood Mononuclear C ell 
PCR  Polymerase -Chain Reaction  
PD Progressive Disease  
PET Positron Emission T omography  
PFS Progression -Free Survival  
PJP Pneumocystis Jiroveci  Pneumonia  
PO per os ; By M outh (orally)  
PPD Cross Product of the LDi and Perpendicular Diameter  
PR Partial Response or Partial Remission  
PS Performance Status  
R-BAC Rituximab -Bendamustine Cytarabine  
RCHOP  Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone  
RPM  Revolutions Per Mi nute 
R/R Relapsed/Refractory  
SAE Serious Adverse E vent 
SCT Stem Cell Transplant  
SD Stable Disease  
SDi Shortest Axis Perpendicular to the LDi  
SPD Sum of the Product of the Perpendicular Diameters of Multiple Lesions  
SQ Subcutaneous  
SRM  Study Reference Manual  
TLS Tumor Lysis S yndrome  
ULN Upper Limit of N ormal  
μmol  Micromole  
US United States  
vs versus  
WBC  White Blood C ell 
WOCBP  Women of Childbearing Potential  
wt Weight  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
9 1. Introduction - Background and Rationale  
1.1 Mantle Cell Lymphoma – Disease Overview  
Mantle cell lymphoma (MCL) is a subtype of Non- Hodgkin Lymphoma (NHL) which is 
considered incurable with conventional therapy. With an incidence of approximately 70,000 
cases diagnosed in the United States  (US) per year, the disease is rare. It typically occurs 
in patients over the age of 60 and 2/3rd of the cases are male.1 
There are three variants of MCL that have different clinical and treatment implications. First 
is considered the typical form of MCL, occurring in 60- 75% of cases. This form typically 
presents with symptomatic disease with lymphadenopat hy and occasionally cytopeni as. 
The second is an indolent form typically presenting with an elevated white blood cell ( WBC ) 
count and circulating lymphoma cells as well as  splenomegaly. This indolent form is 
characterized by an often- slow course and observation alone is recommended i f 
asymptomatic.2 The final form is a blastic variety which is typically quite aggressive, often 
presenting with marked lymphadenopathy and B -symptoms including fevers, chill s, sweats, 
and/or weight loss.  Other than observation in the indolent variety, there is no treatment 
differences between the variants of MCL.  
1.2 Induction Therapy in MCL  
Initial treatment in MCL includes a combination of chemotherapy and immunotherapy. For patients who can tolerate such an approach, an aggressive chemo- immunotherapy regimen 
is utilized to achieve remission. This typically is followed by high dose chemotherapy with autologous stem cell rescue. This approach is too toxic for the majority of patients presenting with MCL given the advanced age at diagnosis. Other approaches have been studied with bendamustine and rituximab (BR) currently considered a standard induction regimen for patients unwilling or ineligible for aggressive therapy.  
BR was first studied by the German cooperative group study evaluating RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristi ne and prednisone) vs. BR in  indolent NHL. The 
MCL cohort included 94 patients and BR had an improved median progression- free survival 
(PFS) over RCHOP (35.4 vs 22.1  months, Hazard Ratio ( HR) 0.49, p=0.0044).
3 Superiority 
of BR over RCHOP was also confirmed in the US through the BRIGHT study.4 Another 
study through the German cooperative group compared FR (fludarabine and rituximab) to 
BR in  indolent NHL. The MCL cohort in this study was 47 patients and again showed 
improved median PFS to BR over FR (17.6 vs. 4.7 months, p=0.01).5 These studies support 
BR as the standard of care for MCL patients unable to be treated with aggressive measures.  
Bendamustine and rituximab is generally well tolerated in this patient population. The only 
elderly MCL study assessing BR showed a Serious Adverse Event (SAE)  rate of 2/63 during 
induction; however, there were deaths during the maintenance phase of this study (3 of 
62).6 Other studies, which include other NHL histologies, show a similar rate of SAE or 
Grade 3/4 non- hematologic toxicities  that occasionally  prompt s withdrawal prior to 
completion of recommended 6 cycles.3,4,5 Deaths during induction are rare.  However, in a 
retrospectiv e study of CLL patients, dose reductions to 70 mg/m2 occurred in half of patients 
over the age of 65, mostly due to neutropenia and infections.7 Of those over the age of 75, 
69% of patients required dose reduction to 70 mg/m2. 7 This has prompted some providers 
to start all patients of very advanced age (over 80) and others with comorbid conditions at 
70 mg/m2 instead of 90 mg/m2 day 1 and 2.  
Maintenance rituximab is more controversial in MCL. Most providers extend maintenance 
rituximab after chemo- immu notherapy induction to MCL patients as it has been shown to 
be superior to observation alone in other histologies of NHL.8 However, the German group 
evaluated maintenance rituximab vs. observation after BR induction in MCL. They found no 
statistical benefit to maintenance rituximab and a suggestion of increased toxicity.9 
However, this study was small and the report was early and only presented in abstract form. 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
10 In a conflicting study, a meta- analy sis showed superiority of  maintenance rituximab in 
MCL.10 At this time, a consensus on this has not been reached.  
1.3 Pending Studies with Bendamustine and Rituximab in MCL  
Many groups have added agents active in relapsed MCL to BR with the goal of inducing 
deeper remissions and prolonging the interval of treatment s. The E1411 intergroup study, 
which recently finished accrual, evaluated BR with or without bortezomib.11 The industry -
sponsored SHINE study, which also recently finished accrual, evaluated BR with or without 
ibrutinib .12 The Nordic LENA -BERIT study evaluated BR with the addition of lenalidomide,13 
and the Italian R -BAC studies have evaluated BR with different doses of cytarabine.14 The 
results of the induction portion of these studies, which are expected within 2 years, will set 
the stage for a Phase III study comparing the most promising BR based regimens. However, 
there are other promising therapies, including venetoclax  that will likely be important in MCL 
within this two year time frame.  This study evaluates venetoclax in combination w ith 
bendamus tine and rituximab. If there is promise in this study, this combination will be 
considered in a larger Phase III study for induction therapy in MCL planned through the US 
cooperative groups.  
Safety in the reported combination studies with BR indicate increased toxicity with additional 
drugs. The LENA -BERIT (BR+ Lenalidomide) study mentioned previously had a Grade 3- 5 
infection rate of 42% (21 of 51) with a death rate during induction of 3 of 51. This was 
considered overly toxic, though the efficacy was high in this study.13 The addition of 
bortezomib and dexamethasone to BR (RiBVD) in 76 older MCL patients showed 4 deaths 
during induction; 1 infection, 1 progressive multifocal leukoencephalopathy (PML) and 2 
cardiac arrests.14 The rate of febrile neutropenia on this study was 11% (11 of 74) and 24 
episodes of infection were identified as SAEs.14 Therefore, there is a suggestion that studies 
combining novel agents with BR show more toxicity than BR alone and should be evaluated closely for toxicity including deaths and infection.  It is known that bendamustine can cause 
delayed lymphocyte recovery and thus atypical infections, such as Pneumocystis Jiroveci  
Pneumonia (PJP), Cytomegalovirus  (CMV) and Herpes Simplex Virus (HSV) are possible 
and have been reported and s een by investigators.
15,16,17 
1.4 Venetoclax (ABT -199, GDC -0199)  
Venetoclax is a novel, oral, highly selective BCL2 inhibitor which is currently Food and Drug Administration ( FDA) approved in relapsed chronic lymphocytic leukemia (CLL) .
18 Inhibition 
of BCL 2, an anti -apoptotic protein that is overexpressed in many NHL’s , allows for apoptosis 
to proceed and induces rapi d cell kill.19 Venetoclax has been studied in various NHL 
histologies as a single agent and in combination with chemotherapy and other targete d 
agents.  
1.4.1  Clinical Efficacy and Safety in MCL and NHL  
Response to single- agent venetoclax has been documented in 28 relapsed MCL 
patients  in a Phase I study evaluating all histologies of NHL. The MCL cohort had  
an overall response rate ( ORR) of 75% (n=21) with few complete responses (CR s) 
(n=6, 21%).20 Given the risk of TLS, the dose of venetoclax was increased from 20 
mg to the target dose over several weeks. The ending dose was 200 mg (n=1), 400 mg (n=9), 600 mg (n=4), 800 mg (n=7), 900 mg (n=1) and 1200 mg (n=6). There was no difference in efficacy between these doses and the target dose going 
forward for MCL is 400 mg orally ( PO) daily. Additional studies evaluating 
combinations of venetoclax with chemotherapy and other targeted agents are on -
going.  
Venetoclax is generally safe though the majority of patients will experience a 
treatment emergent adverse event. Common side effects in NHL are mostly hematologic including neutropenia (Grade 3 or 4: 14.8%), febrile neutropenia 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
11 (Grade 3 or 4:  2.2%), thrombocytopenia (Grade 3 or 4: 9.6%), and anemia (Grade 
3 or 4:  14.8%). Gastrointestinal (GI) toxicities including nausea and diarrhea are 
also common but tend to be low grade (all grade 47%, Grade 3 or 4 <1%). 
Infections, mostly being upper respiratory can also be s een with venetoclax. Please 
see the Investigator Brochure  (IB) and prescribing information for more detail.21,22 
1.4.2  Venetoclax Clinical Pharmacology21 
Venetoclax is dosed daily with good bioavailability. In NHL, plasma concentrations peaked at approximately 4- 8 hours after doses between 50 and 400 mg daily and 
had a half -life of 14.1 to 18.2 hours. Absorption is improved with a meal or snack. 
Venetoclax and its metabolites are metabolized by CYP34A and is excreted through 
the bile duct and feces. There is minimal renal excretion. A Phase I study evaluating 
venetoclax with bendamustine did not suggest a change in pharmacokinetics with bendamustine administration.  
1.4.3  Dose Rationale  
Preclinical studies have evaluated venetoclax  as a chemotherapy sensitizer, 
suggesting that venetoclax can sensitize cancer cells to chemotherapy .
23,24,25 An 
interim analysis of a clinical trial in follicular lymphoma has demonstrated that BR plus venetoclax is tolerable and active, though more Grade 3- 4 events occurred in 
the venetoclax containing arm.
26 The activity of venetoclax in MCL combined with 
the preclinical rationale and the safety data in follicular lymphoma suggest that a Phase II study of BR + venetoclax is warranted in MCL.  Dosing with chemot herapy 
has not been optimized. The follicular lymphoma study utilized continuous dosing of venetoclax with BR and demonstrated a Grade 3- 4 Adverse Event (AE)  rate of 
78% compared to 46% without venetoclax.
24 We hypothesize that intermitt ent 
dosing of venetoclax will still improve efficacy over BR alone but will be better  
tolerated.  
Venetoclax can induce clinically significant TLS in CLL  with the first dose of drug.19 
The risk of TLS necessitates careful dose titration of the drug and sometimes admission for hydration and TLS monitoring.  Tumor lysis has also been seen in 
MCL, but to a lesser degree and usually in the setting of high tumor burden (verbal communication, unpublished data).  Thus, in MCL, careful upward dose titration is 
still n eeded. In this study, we will start with 20 mg of venetoclax and increase the 
dose weekly to a maximum dose of 400 mg by Cycle 2, Day 1 . 
1.5 MRD M onitoring in MCL  
The absence of Minimal Residual Disease (MRD) is a powerful predictor of outcome after 
induct ion in MCL.  MRD can be measured in many ways but the most sensitive is a 
polymerase- chain reaction ( PCR ) based test quantifying the presence of a clonal 
immunoglobulin heavy chain re- arrangement or t(11;14) .27,28 A combined analysis of 
transplant eligible and ineligible patients (MCL Younger and MCL Elderly studies) showed 
MRD positive patients consistently had an adverse PFS after all induction treatment (chemotherapy in MCL Elderly and chemotherapy followed by autologous stem cell 
transplant ( SCT) in MCL Younger) .
29 Patients in clinical remission after induction also have 
a survival advantage if there is no MRD detected at that time.29 Thus, MRD is a quick, 
meaningful surrogate of PFS and overall survival ( OS) after induction therapy in MCL 
patients.  
1.6 S ummary of Rationale for Proposed Study  
To summarize, there are several pending studies combining various agents with what is considered a standard therapy, bendamustine and rituximab, in MCL patients ineligible for aggressive therapy. This study seeks to add venetoclax, a promising single agent in MCL, to BR with plans to add this regimen, if promising, to a larger Phase III study of various BR 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
12 combinations in MCL.  
Given the risk of TLS in MCL, venetoclax  dose will be escalated through Cycle 1 with close 
monitoring of TLS. The monotherapy dose of venetoclax moving forward in MCL is 400 mg 
daily and there is no suggestion that combination with BR will change the pharmacokinetics 
of venetoclax. Thus, the maximum dose of 400 mg PO daily will be used from Cycle 2 
onward. Given toxicity seen in the follicular lymphoma study combining BR with continuous venetoclax, we will utilize venetoclax as a chemosensitizer and only treat for 10 days with each cycle. Mainten ance rituximab will be allowed per investigator discretion given the 
complexity of the issue in MCL after BR therapy.  
We plan to utilize a CR rate of 70% as a historical control based on early evaluation of  the 
induction therapy of E1411.
29 To be considered promising, we hope to improve this by 15% 
to 85%. CR is our primary outcome to allow for a quick readout and allow for potential inclusio n in a future randomized study.  We will also monitor MRD via PCR based methods 
throughout the study as an exploratory  objective. 
1.6.1  October  11, 2021: Revised Summary  of Rationale  
Preliminary data from a similar cohort of patients  as that  enrolled in this study 
indicates that post -induction CR rate is 60%, not 70% as initially assumed. In 
addition, the observed study accrual rate ( 1.1 patients/month) is significantly lower 
than the planned/expected study accrual rate of 2.3 patients/month. For both reasons, the study was redesigned to reflect the current historical CR rate and with a lowered sample size for prompt primary endpoint readout. Accrual before this 
redesign is 25 patients.  
A 17% increase in CR rate  from 60% (null)  to 77%  (alternate) is of interest . 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
13 2. Study Objectives 
2.1 Primary Objective  
To determine the CR rate of BR + venetoclax  in untreated MCL patients over the age of 60 
years.  
2.2 Secondary Objectives 
● Evaluate the safety of the combination, with particular attention to TLS incidence with 
Cycle 1.  
● To determine the overall  response rate (complete response [ CR] + partial response 
[PR]) of BR  + venetoclax in untreated MCL patients over the age of 60 years . 
● To determine the survival (progression- free survival [PFS]  and overall  survival [OS] ) of 
MCL patients treated with BR + venetoclax induction.  
2.3 Exploratory Objectives  
• Bone marrow aspirate and peripheral blood assessed minimal residual disease ( MRD ) 
negative rate of BR + venetoclax in untreated MCL patients over the age of 60 years . 
• Evaluate the utility of morphologic assessment of bone marrow biopsy and aspir ation 
when combined with peripheral blood MRD and PET assessments on CR rate at end 
of treatment.  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
14 3. Selection of Patients  
Each of the criteria in the checklist that follows must be met in order for a patient to be considered 
eligible for this study. Use the checklist to confirm a patient’s eligibility. For each patient, this checklist must be photocopied, completed and maintained in the patient’s chart.  
In calculating days of tests and measurements, the day a test or measurement is done is considered Day 0. T herefore, if a test is done on a Monday, the Monday four weeks later 
would be considered Day 28.  
PrECOG Patient No.    
Patient’s Initials (  F, M, L )   
Physician Signature and Date   
NOTE:  PrECOG  does not allow  waivers to any protocol specified criteria. A ll eligibility criteria listed 
in Section 3 must be met, without exception. All questions regarding clarification of eligibility criteria must be directed to the Medical Monitor or PrECOG Study Contact . 
NOTE:  Institutions may use the eligibility checklist as source documentation if it has been reviewed, 
signed, and dated prior to registration by the treating physician.  
3.1 Patients must have histologically confirmed (biopsy- proven) diagnosis of mantle cell 
lymphoma (MCL) , with documented cyclin D1 (BCL1) expression by immunohistochemical 
stains and/or t(11;14) by cytogenetics or FISH .
30 
Date of Diagnosis: _____________  
3.2 Patients must  have measurable or evaluable disease  as defined as a lymph node measuring 
>1.5 cm in any dimension or splenomegaly with spleen >15 cm in craniocaudal dimension. 
3.3 Age ≥ 60 years.  
3.4 No intention to undergo consolidation with high dose chemotherapy and autologous stem 
cell rescue (Autologous Stem Cell Transplant) in first remission.  
3.5 ECOG performance status of 0- 2 (Appendix I). 
Performance Status: Please circle  0 1 2 Date: ___________  
3.6 Ability to understand and willingness to sign IRB -approved informed consent.  
3.7 Willing to provide mandatory tissue samples (if sufficient tissue available), bone marrow and blood samples for research purposes (Section 13). 
3.8 Adequate organ function as measured by the following criteria, obtained ≤ 2 weeks prior to 
registration:  
• Absolute Neutrophil Count (ANC)  ≥ 1000/mm
3 unless there is bone marrow involvement  
or splenomegaly  
ANC: __________________ Date of Test: ____________ 
• Hemoglobin ˃8.0 g /dL 
Hemoglobin: ____________ Date of Test: ____________ 
• Platelets  ˃75,000/mm3 or ˃50,000 /mm3 if there is bone marrow involvement  or 
splenomegaly  
Platelets: _______________ Date of Test: ____________ 
 _____  
_____  
_____  
_____  
_____  
_____  _____  
_____  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
15 • Creatinine Clearance ≥ 40 mL/min  
Creatinine Clearance: ______  Date of Test : ___________ _ 
NOTE:  Acceptable Measures of Creatinine C learance: C ockcroft -Gault formula 
(Appendix II or direct measured creatinine clearance [by 24 hour urine 
collection or other methods ]). 
• Total Bilirubin ≤ 1.5x upper limit of normal  (ULN) or ≤ 3x ULN for patients with 
documented Gilbert’s syndrome  
Total Bilirubin: ___________ ULN: ________  Date of Test: ___________  
• Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT)  ≤ 2.5x ULN  
AST: ______________  ULN: _______  Date of Test: ___________  
ALT: ______________  ULN: _______  Date of Test: ___________  
3.9 All females of childbearing potential (not surgically sterilized and between menarche and 1 
year post menopause) must have a blood test to rule out pregnancy within 2 weeks prior to registration.  
Is the patient a woman of childbearing potential? _____________________ (yes/no)  
If yes, Date of Test: _______________  Results: ____________________________  
3.10 Women must not be pregnant or breastfeeding. Females of childbearing potential who are 
sexually active with a non- sterilized male partner  and sexually active men must agree to 
use 2 methods of adequate contraception (hormonal plus barrier or 2 barrier forms) prior to study entry, for the duration of study participation, and for 12 months after last dose of 
therapy. Method of contraception must be documented.  
NOTE:  Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.  
3.11 Patients should not have prior chemotherapy, radiotherapy or immunotherapy for lymphoma.  
• Corticosteroids used for other non- lymphomatous conditions will be allowed.  
• Corticosteroids no greater than 1 mg/kg prednisone (or equivalent)  given for ≤ 14 days 
will be allowed for treatment of lymphoma related symptoms.  
3.12 Patie nts must have no recent (<1 year) history of malignancy except for the following:  
• adequately treated non- melanoma skin cancer  
• adequately treated Stage I melanoma of the skin  
• in situ  cervical cancer  
• low grade prostate adenocarcinoma (Gleason grade ≤ 6) managed with observation 
and stable for 6 months.  
NOTE:  Any malignancy treated with curative intent and disease free without treatment for 
≥ 1 year prior to enrollment may be included. 
3.13 Patients should not have known evidence of central nervous system ( CNS ) lymphoma. 
3.14 Patients must not have received a prior allogeneic stem cell transplant or solid organ 
transplant (except for cornea) for any i ndication.  
3.15 Patients must have no active, uncontrolled infections.  
 _____  _____  
_____  
_____  
_____  
_____  
_____  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
16 3.16 Patients must not have active hepatitis B or be chronic carriers of hepatitis B. This is defined 
as patients with hepatitis B surface antigen (HBsAg) positive.  Patients with prior exposure 
to hepatitis B (hepatitis B core antibody  (anti-HBc) positive AND HBsAg  negative) are 
allowed with a protective level hepatitis B surface antibody AND a negative  hepatitis B viral 
load by polymerase- chain reaction ( PCR ). 
3.17 Patients must not have active hepatitis C  (HCV)  as defined by a hepatitis C  viral load 
detectable by PCR. Patients with a negative HCV antibody are assumed to have a negative 
HCV viral load. Patients with a positive HCV  antibody must have a negative hepatitis C viral 
load by PCR. Prior tre atment for an active HCV infection will be allowed as  long as the 
hepatitis C viral load by PCR is negative.  
3.18 Patients must not have known active Human Immunodeficiency Virus  (HIV). Testing not 
required in absence of clinical suspicion.  
3.19 Patients must not have evidence of significant, uncontrolled concomitant diseases , including 
psychiatric diseases,  that could affect compliance with the protocol or interpret ation of 
results  or that could increase risk to the patient.  
3.20 Patients must not have conditions that preclude oral administration or absorption of medications through the GI tract, including but not limited to the inability to swallow pills or  
malabsorption syndromes.  
3.21 Patients must not have known allergies to both xanthine oxidase inhibitors and rasburicase. 
3.22 Patients must not require the use of warfarin. Blood thinners of other classes are permitted.  
3.23 Patient may  not receive the following agents within 7 days prior to the first dose of 
venetoclax:  
• Strong and moderate CYP3A inhibitors  
• Strong and moderate CYP3A inducers  
• Strong and moderate P- gp inhibitors  
NOTE:  Continuous use of strong and moderate CYP3A inhibitors , CYP3A inducers  or P-
gp inhibitors  is not allowed. If a subject requires continuous use of these drugs they 
will need to be excluded . Please refer to Section 6.2.2  and Appendix III “Additional 
Excluded and Cautionary Medications” for further det ails. 
3.24 Patients must not have consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of venetoclax . _____  
_____ 
_____  
_____  
_____  
_____  _____  
_____  _____  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
17 4. Registration Procedures 
4.1 Ethics  
This study will be conducted in accordance with the ethical principles that have their origin 
in the current Declaration of Helsinki and will be consistent with applicable US regulatory requirements and International Conference on Harmonization/Good Clinical Practice  
(ICH/ GCP).  
The study will be conducted in compliance with the protocol. The protocol and any 
amendments and the patient informed consent will receive Institutional Review Board (IRB) 
approval prior to initiation of the study.  
Freely given written informed consent must be obtained from every patient or their legally 
acceptable representative prior to clinical trial participation, including informed consent for any screening procedures conducted to establish patient eligibility for the trial.  
Study personnel  involved in conducting this trial will be qualified by education, training, and 
experience to perform their respective task(s). This trial will not use the services of investigators or study personnel where sanctions have been invoked or where there has been scientific misconduct or fraud (e.g., loss of medical licensure, debarment). 
Investigators are responsible for the conduct of the study at their study site.  
4.2 Regulatory Requirements  
Before a site may enroll patients, protocol -specific regulatory and other documents must be 
submitted to PrECOG as noted in study materials. Detailed information regarding document submission and control is provided to each site in separate study materials.  
Once required documents are received, reviewed, and approved by PrECOG or their 
representative, a Study Reference Manual (SRM) will be forwarded to the site. Any changes to site regulatory documents must be submitted by the investigator to the responsible party 
in a timely manner. Initial study drug shipment will not occur until the regulatory packet is 
complete. Once PrECOG activates a site, enrollment ma y occur. No patients will begin 
protocol therapy without formal registration as per the process below.  
4.3 Patient Registration  
After written informed consent has been obtained, protocol -required assessments will be  
performed.  
Patients must meet all of the eligibility requirements listed in Section 3 prior to registration. Patients must not start protocol treatment prior to registration. Treatment should begin ≤ 10 
worki ng days from study entry (date of registration).  
An eligibility checklist is included in Section 3. A confirmation of eligibility assessment by 
the investigator and/or site will be performed during the registration process . 
Upon determination that a subject meets eligibility criteria, the subject will be registered in 
the study by site personnel via an electronic data capture (eDC) system.  
Full information regarding registration procedures and guidelines can be found in the SRM 
provided. C orrespondence regarding patient registration must be kept in the study records . 
4.4 Research Tissue, Bone Marrow and Blood Samples  
Pre-treatment, diagnostic pathology specimens (organ or lymph node biopsy or excision) 
obtained in the course of standard biopsy or surgery are required for enrollment  (if sufficient 
tissue is available, submission is mandatory). However, if there is insuffi cient tissue 
availa ble for sample submission (i.e. < 10 slides ) patients may still be enrolled to the trial.  
 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
18 NOTE:  If block s and/or slides are unavai lable  and bone marrow  is involved with mantle cell 
lymphoma, obtain  two 2  mL EDTA tubes of bone marrow aspirate (one for baseline 
MRD analysis and one for future research). If blocks/slides and bone marrow are 
unavailable and peripheral blood is involved with mantle cell lymphoma obtain one 
4 mL and one 6 mL EDTA tubes of peripheral blood (one for baseline MRD analysis 
and one for future research).  If baseline samples (blocks/slides, bone marrow, 
and/or peripheral blood) are not submitted at baseline for MRD  (i.e., not involved 
with mantle cell lymphoma), then patients will be allowed to remain on study but 
MRD samples will not be collected during the study.  
If bone marrow procedure is completed per standard of care, mandatory bone marrow 
aspirate sample for MRD analysis will be collected at the end of treatment.  Please note,  if 
bone marrow is positive for mantle cell lymphoma at baseline, an end of treatment bone 
marrow must  be collected to confirm response.  
Mandatory  peripheral blood samples  for MRD analysis will  be collected  at the end of 
treatment . 
Optional peripheral blood samples will also be collected for future research.  
Optional: At time of progression, biopsy and peripheral blood samples are requested to 
be sent for correlative studies and banked for future research.  
NOTE:  No bone marrow biopsy/aspirate or tissue biopsy should be performed solely for the 
purposes of obtaining research samples.  
Time points for tissue, bone marrow and blood samples are outlined in the study parameters 
(Sectio n 10) and specific requirements are outlined in the correlative section of this protocol 
(Section 13) and the  PrE0405  lab manual.  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
19 5. Treatment Plan  
5.1 Overview  
Eligible patients will be treated in a single arm with venetoclax, bendamustine and rituximab 
as induction therapy for 6 cycles  of 28 ± 3 day length as outlined in Table 5-1. After 6 cycles, 
maintenance rituximab may be administered per physician discretion. The recommended 
schedule for maintenance rituximab is  every 8 ± 2 weeks for 12 doses or 24  months 
(whichever comes first) . 
Table 5-1: Treatment Overview  
Agent  Route  Dose  Days  
Venetoclax  Oral 20 mg  
50 mg  
100 mg  
200 mg  
400 mg  Day 1 -7 (Cycle 1 only)  
Day 8 -14 (Cycle 1 only)  
Day 15 -21 (Cycle 1 only)  
Day 22 -28 (Cycle 1 only)  
Day 1 -10 (Cycle 2- 6) 
Bendamustine  IV 90 mg/m2a Day 1 and 2 (Cycle 1- 6) 
Rituximabb IV 
SQ (optional) 375 mg/m2 
1400 mg (optional)  Day 1 (Cycle 1 -6b) 
Day 1 (Cycle 3 -6) (optional)  
a Per investigator discretion, bendamustine  may be started at 70 mg/m2 in patients over 
the age of 75 years with comorbid conditions or patients over the age of 80 years without 
comorbid conditions.  
b Rituximab should be administered as 375 mg/m2 IV on day 1 of each cycle. If the first 
two cycles of rituximab (or two consecutive cycles)  are well tolerated, IV rituximab may 
be replaced with 1400 mg/23,400 units subcutaneous ( SQ) rituximab/hyaluronic acid on 
Day 1 of Cycles 3 -6 (or after 2 consecutive cycles are well tolerated) , per 
rituximab/hyaluronic acid package insert.  Biosimilars for rituximab  are permitted. 
All doses are based on actual body weight.  
Prophylactic filgrastim, pegfilgrastim or pegfilgrastim on body injector  (OBI)  or biosimilars  
will be administered for all patients on study per Section 5.5. 
Pneumocystis Jiroveci  Pneumonia (PJP)  and antiviral prophylaxis will be initiated in all 
patients (Section 5.6) . 
Section 5.7 for Monitoring of Cytomegalovirus (CMV).  
Premedication: Acetaminophen and diphenhydramine should be administered prior to 
each infusion or injection of rituximab, per institution guidelines. Other prophylactic 
medications may be administered per institution guidelines.  
Antiemetic T herapy:  Standard anti -emetic therapy may be given to patients prior to 
administration of bendamustine  per institutional guidelines. However, 5- HT3 serotonin 
receptor agonist and steroids are strongly recommended.  
Tumor lysis syndrome (TLS)  is an event of interest and will be monitored closely during 
therapy.  TLS will be assessed by the Data Safety and Monitoring Board (DSMB) among the 
first 19 patients  accrued to this study who received venetoclax treatment for at least 3 cycles 
with no hold to accrual.  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
20 5.2 Treatment and Administration Schedule  
Venetoclax must be administered before bendamustine and/or rituximab. Bendamustine 
and rituximab may be given in any order ( venet oclax, bendamustine, rituximab or 
venetoclax, rituximab, bendamustine).  One cycle=28 day s. 
5.2.1 Venetoclax A dministration 
Venetoclax will be administered once daily and, given risk of tumor lysis syndrome 
in MC L, will be dose escalated with C ycle 1 , as per Table 5-1 and Table 5-2. In 
Cycles 2 -6, venetoclax will be given at 400 mg oral daily  for 10 days  starting on day 
1. Venetoclax should be given prior to administering bendamustine or rituximab on 
day 1 of each cycle. Venetoclax will be supplied in 10 mg, 50 mg and 100 mg tablets 
and administration instructions are listed in Table 5- 2. 
Table 5- 2: Venetoclax D osing  
Days  Total Daily D ose Administration I nstructions  
Cycle 1  
Day 1 -7 20 mg PO daily  Take two 10 mg tablets PO daily  
Day 8 -14 50 mg PO daily  Take one 50 mg tablet PO daily  
Day 15 -21 100 mg PO daily  Take one 100 mg tablet PO daily  
Day 22 -28 200 mg PO daily  Take two 100 mg tablets PO daily  
Cycle 2 -6 
Day 1 -10 400 mg PO daily  Take four 100 mg tablets PO daily  
Day 11 -28 No venetoclax administered.  
Venetoclax should be administered with a meal  and swallowed whole with an 8-
ounce glass of water . If vomiting occurs within 15  minutes after taking venetoclax  
and all expelled tablets are still intact, another dose may be given. Otherwise, no 
replacement dose is to be given.  
If patient  misses a dose of venetoclax within 8 hours of when it is usually taken, the 
patient should take the dose as soon as possible and resume normal daily dosing schedule. Should the dose be missed by greater than 8 hours, the dose should be skipped and patient should resume normal daily dosing the following day. This dose should not be made up.  
Patient compliance in taking assigned daily dose of venetoclax will be assessed by pill counts and IRB reviewed medication diary  (provided to sites) . Bottles containing 
venetoclax tablets will be given to patients at regularly scheduled visits. Previously 
distributed bottles will be returned to t he clinic. A medication diary will be given to 
document compliance.  
5.2.1.1  Adherence  
Medication  diaries will be maintained on all patients taking venetoclax. 
Diaries will be completed by patients and subsequently r eviewed by the 
research staff with the patient at the following visit s (Cycle 1 Day 8, Cycle 
1 Day 15, Cycle 1 Day 22, Cycle 2- 6 Day 1). Pill counts of venetoclax will 
also be performed and recorded at Cycle 1 Day 8, Cycle 1 Day 15, Cycle 1 Day 22, Cycle 2- 6 Day 1  by the research staff and documented on the 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
21 drug accountability record. If the pill count is discrepant with the drug 
diary, the pill count will be used to determine adherence status. Patients may be counseled by the study doctor regarding adherence issues.  
5.2.2 Bendamustine Dosing  
Bendamustine will be administered as 90 mg/m
2 as IV infusion on days 1 and 2 of 
each 28 day cycle per institution guidelines. Subjects with advanced age or other comorbid conditions are known to have more side effects with bendamustine at 90 mg/m
2.7 Per investigator discretion, bendamustine may be administered as 
70 mg/m2 is IV infusion on days 1 and 2 in patients over 75 years with comorbid 
conditions or over 80 years without comorbid conditions.  
Bendamustine must be given after venetoclax but may be given before or after 
rituximab.  
5.2.3  Rituximab A dministration  
Rituximab should be administered on day 1 of each 28 day cycle after 
administration of venetoclax . Rituximab should be given as  a “standard”  IV infus ion 
at 375 mg/m2 for Cycle 1 per institution guidelines and package insert.  For patients 
that do not have a Grade 3- 4 infusion related adverse event , Cycle 2 -6 may be 
given as a “rapid” IV infusion at 375 mg/m2 per institutio n guidelines and package 
insert . Patients that do have a G rade 3- 4 infusion related adverse event should 
receive the “standard” infusion rate for the subsequent cycle. Patients may receive the “rapid” infusion schedule if the prior infusion was not associated with a G rade 
3-4 infusion related adverse event.  Biosimilars for rituximab are permitted. 
Patients who did not have a Grade 3- 4 infusion related adverse event with the first 
2 cycles of IV rituximab (or two consecutive cycles) , may be switched to SQ  
rituximab/hyaluronic acid at a dose of 1400 mg/23,400 units on Day 1 of C ycles 3 -
6 (or after 2 consecutive cycles are well tolerated)  according to package insert and 
institution guidelines . This is per patient and institution preference. Patients may be 
switched back to IV rituximab at any time and switching to SQ rituximab is not required.  
All doses of rituximab should be administered with acetaminophen and diphenhydramine (or another anti -histamine) pre -medicati on per institution 
guidelines. Other pre- medications may be utilized per institution guidelines.  
Rituximab must be given after venetoclax but may be given before or after bendamustine.  
After 6 cycles of venetoclax, bendamustine and rituximab, subjects responding to therapy may receive maintenance rituximab IV or SQ  (one dose ever y 8 ± 2 weeks 
for 12 doses or 24 months  whichever comes first) per physician and patient 
preference.  
5.3 Tumor Lysis Prophylaxis  
TLS is a risk for MCL patients treated with venetoclax. The highest risk for TLS occurs within the first 24 hours of a dose escalation. Ramp up dosing helps to mitigate this risk however, careful prophylaxis of TLS is required, including the following:  
• Allopurinol 300 mg PO daily MAY be given if the risk of TLS is thought to be higher than 
the risk of Steven -Johnson syndrome. If A llopurinol is given, we recommend starting 24 
hours prior to Cycle 1, Day 1 and continue through at least Cycle 2, Day 10. Allopurinol 
can continue longer per treating physician discretion.  
• One liter of IV fluids on Day 1 of Cycle 1 and Cycle 2  of chemotherapy.  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
22 • Encourage oral hydration of at least 2 liters of any form of fluid per day starting 24 hours 
prior to Cycle 1, Day 1 and continuing until Cycle 2, Day 10.  
• Rasburicase is allowed per institutional guidelines.  
• Additional IV fluids and monitoring for TLS is allowed per treating physician discretion. 
• What is listed in the protocol are minimum standards.  
o Admission to the hospital is allowed for advanced treatment and monitoring of TLS 
per treating physician discretion/institutional standards . 
NOTE : Defined risks for TLS are not clear in MCL but some higher risk situations include:  
 Bulky disease (any lymph node mass >10 cm)  
 Circulating mantle cell lymphoma with Absolute Lymphocyte Count ( ALC) >25 
x 109/L 
 Borderline renal function  
 Rapidly progressing disease.  
5.4 Tumor Lysis Monitoring  
Tumor lysis syndrome (TLS) has been documented in patients treated with single agent 
venetoclax in other studies. Tumor l ysis is most common within the first 24 hours of a dose 
increase of venetoclax. It is an outcome of interest in the current study and will be monitored 
closely  in patients with C ycle 1 and Cycle 2. 
Tumor lysis laboratory studies include the following: Basic Metabol ic Panel (Sodium, 
Potassium, Chloride, Bicarbonate  (HCO 3), BUN, Creatinine,  Calcium) , Album in, Uric Acid , 
and Phosphorus. Monitoring for TLS is listed in Table 5- 3. 
Table 5- 3: Tumor Lysis M onitoring  
Days  Dose of Venetoclax  TLS Lab T iming  
Cycle 1  
Day 1  20 mg PO  - Prior to dosing Venetoclax  
- 6-8 hours after dosing Venetoclax  
Day 2  20 mg PO  Prior to dosing Venetoclax  and Bendamustine  
Day 8  50 mg PO  - Prior to dosing Venetoclax  
- 6-8 hours after dosing Venetoclax  
Day 9  50 mg PO  Prior to dosing Venetoclax a 
Day 15  100 mg PO  - Prior to dosing Venetoclax  
- 6-8 hours after dosing Venetoclax  
Day 16  100 mg PO  Prior to dosing  Venetoclax a 
Day 2 2 200 mg PO  Prior to dosing Venetoclax  
Day 2 3 200 mg PO  Prior to dosing Venetoclax a 
Cycle 2  
Day 1  400 mg PO  - Prior to dosing Venetoclax  
- 6-8 hours after dosing Venetoclax  
Day 2  400 mg PO  Prior to dosing Venetoclax  and Bendamustine  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
23 Cycle 3 -6 
Day 1  400 mg PO  Prior to dosing Venetoclax  
a Can be performed locally.  
Venetoclax  dose may be given prior to results returning on Cycle 1 : Days 9, 16, 23; and 
Cycle 4 -6: Day 1.  
Venetoclax should not be administered prior to results returning on Cycle 1: Days 1,  2, 8, 
15, 22;  Cycle 2 : Days 1 and 2; and Cycle 3: Day 1. 
5.5 Neutropenic Sepsis Prophylaxis  
Bendamustine and venetoclax can cause neutropenia. Prophylaxis for neutropenic sepsis 
and febrile neutropenia is required with one of the following (Growth Colony Stimulating 
Factors [GCSFs]) to be administered 24-72 hours after the last dose of bendamustine for 
each cycle.  
• Pegfilgrastim SQ 6 mg once 
• Pegfilgrastim SQ 6 mg via on- body injector (OBI) once  
• Filgrastim  or filgrastim -sndz SQ 300 or 480 mcg for 5 days  
• Biosimilars are also allowed for prophylaxis for neutropenic sepsis and febrile 
neutropenia  
5.6 Infection Prophylaxis  
All patients must be initiated on prop hylaxis for PJP  at the time of Cycle 2 of venetoclax, 
bendamustine and rituximab. However, PJP prophylaxis may be administered with Cycle 1 
if the treating physician feels the risk of PJP is higher than the risks during the venetoclax 
dose ramp up. Trimethoprim -sulfamethoxazole (Bactrim ) is the preferred treatment of 
choice for PJP prophylaxis. PJP prophylaxis should continue until  6-8 weeks from Day 1 of 
last completed induction cycle. PJP prophylaxis may be discontinued at that time, or continued at the discretion of the treating physician . If the patient will not be able to take 
trimethoprim -sulfamethoxazole then alternatives include: Dapsone, Pentam idine (aerosol) 
or Atovaquone. (The myelosuppressive effects of trimethoprim -sulfamethoxazole when 
administ ered in prophylactic doses is minimal.)  
Patients must also be initiated on acyclovir or valcyclov ir as prophylaxis against Herpes 
Simplex and Varicella Zoster  viral infections.  Antiviral prophylaxis should continue for a 
minimum of 6 months after completion of induction, and may be discontinued at that time, or continued at the discretion of the treating physician. 
If lymphopenia is documented (absolute lymphocyte count <500), then the investigator may 
choose to continue prophylactic medications for a longer duration.  
NOTE:  The above mentioned prophylactic medications have no known interactions with the 
study drugs . 
5.7 Monitoring for  Cytomegalovirus  (CMV)  
Patients will be monitored for CMV reactivation using Quantitative PCR assay for CMV DNA.  
Induction Phase:  Quantitative PCR will be checked once a month and at the end of 
induction . 
Maintenance Phase:  Treating physician  discretion or per institutional standards ; however, 
if the CMV level at the end of induction is detectable, it is recommended to continu e 
monitoring CMV PCR per institutional standards . 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
24 There are four possible results:  
● Not detected  
● CMV DNA detected <137 IU/m L 
● CMV DNA detected between 137 and 9,100,00 0 IU/m L 
● CMV DNA detected >9,100,000 IU/m L 
If CMV PCR  is reported as >137 IU/mL, then the frequency of testing for the PCR needs to 
be changed to weekly monitoring.  
If CMV PCR is >500 IU/ml and the trend is rising, on subsequent weekly measurements 
then: 
● The study treatment will be held  
● Preemptive CMV therapy will be initiated as per institutional guidelines in conjunction 
with Infectious disease specialist s 
NOTE:  CMV testing will likely be reported in ~ 48- 72 hours and the patient may have 
received all the study drugs and may or may not be receiving venetoclax.  
Study drugs may be restarted without dose reduction after resolution of  asymptomatic  
CMV reactivation if all the following conditions are met:  
● CMV reactivation is resolved as determined by the investigator 
● The CMV reactivation was NOT associated with any known end organ disease ( for 
example: pneumonitis, hepatitis, gastroenteritis, retinitis, encephalitis ) 
● Patient is deemed clinically appropriate to restart therap y 
Once treatment is restarted, secondary prophylaxis must be maintained per institutional 
guidelines.  
If there is associated end organ damage, patient will be removed from  study.  
 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
25 6. Dose Delays & Modifications  
All toxicities should be graded according to the National Cancer Institute (NCI) Common 
Terminology Criteria for Adverse Events Version 5.0 (CTCAE V5 .0). A copy of the CTCAE  
V5.0 can be downloaded from the CTEP website (http://www.ctep.cancer.gov ). 
A 3 day window is allowed for scheduled therapy, tests  and/or results  except as noted for TLS 
monitoring . Delays due to holidays, weekends, bad weather or other unforeseen circumstances will 
be permitted. 
If administration of venetoclax, bendamustine or rituximab  is delayed on day 1 of a cycle, the 
administration of all the agents should be delayed for the same timeframe. For example, if 
bendamustine is delayed, administration of venetoclax and rituximab should also be delayed so that they are given together beginning on Day 1 of the same cycle (Cycle 1 cannot be more than 49 
days) . 
NOTE : For CMV reactivatio n and infection management, please refer to Section 5.7  
If any of the study drugs are permanently discontinued (i.e., Grade 4 infusion- related reaction with 
rituximab), the patient will be removed from study  and followed per Section 7.2 . 
NOTE:  TLS will be considered as laboratory or clinical TLS per Appendix IV. 
6.1 Dose Modifications  
6.1.1  Hematologic Toxicities  
Table 6- 1: Dose Modifications  and Delay  for Hematologic Toxicity  
 GCSF will be ad ministered to all patients per S ection 5.5. 
 If a cycle is delayed by >28 days, then patient will discontinue study  treatment.  
 Best supportive care should be offered to all patients per Section 6.2.  
 Refer to Table 6-4 for D ose Modifications . 
Event  Dose Delays or M odifications  
During Cycle 1 : 
• Febrile neutropenia  
• Grade 4 thrombocytopenia  
• Grade 3 thrombocytopenia 
with bleeding  - Hold venetoclax until febrile neutropenia resolves, ANC recovers to >1000/mm3 
and/or platelets recover to >50,000/mm3. Resume venetoclax dosing. 
- There may be a prolongation of C ycle 1 by up to 28 days. In general, after 
resuming venetoclax , please allow for 7 (+/ - 1) days with each dose increase. 
Cycle 1 cannot be more than 49 days . 
At Start of Cycle 2 -6: 
• Grade 3 or 4 neutropenia or 
thrombocytopenia  - Hold all protocol therapy  and delay cycle for at least 7 days and up to 2 8 days . 
- Once ANC resolves to > 1000/mm3 and/or platelets  resolve >75,000/mm3, resume 
cycle as below:  
o For first occurrence:  
 If hold was ≤ 10 days, resume cycle at Dose L evel 0. 
 If hold was >10 days, resume cycle at Dose L evel -1. 
o For second occurrence of any length: 
 Resume cycle at Dose Level -1. 
o For any occurrence after a cycle at Dose Level -1. 
 Resume cycle at Dose Level -2. 
o For a ny occurrence after a cycle at Dose Level -2. 
 Subject  will discontinue  study  treatment . 
During Cycle  2-6: 
• Febrile neutropenia  
• Thrombocytopenia with 
bleeding  - If taking venetoclax  (Days 2 -10), hold venetoclax until next cycle AND  
- For subsequent cycles, resume at Dose Level -1. 
- If recurre nce, dose subsequent cycles at Dose Level -2. 
- For third rec urrence, subject  will discontinue  study  treatment . 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
26 6.1.2  Non-Hematol ogic Toxicities  
Table 6- 2: Dose Modifications and Delay  for Non-Hematologic Toxicity  
 Dose modifications should occur only for treatment emergent and related toxicities . 
 Dose reductions should be made to the attributed drug. No dose reductions in rituximab are 
permitted. If both venetoclax and bendamustine are attributed to the AE of interest, venetoclax 
must be dose reduced; however, bendamustine may also be dose reduced per investigator 
discretion.  
 If a cycle is delayed by >28 days, then patient will discontinue study  treatment.  
 Best supportive care should be given to all patients according to S ection 6.2. 
 Refer to Table 6- 5 and Table 6-6 for Dose Modifications . 
Event  Dose Delays and Modifications  
Grade 3 to 4 Non-Hematologic 
Toxicity  
(not otherwise described) 
• excluding alopecia  - During Cycle 1, hold all study treatment and resume once G rade ≤ 1. 
o Resume venetoclax  treatment and dose escalation at the dose the toxicity 
occurred.  
o There may be a prolongation of Cycle 1 by up to 2 8 days. In general, after 
resuming venetoclax, please allow for 7 (+/ - 1) days with each dose increase.  
Cycle 1 cannot be more than 49 days.  
o Re-challenge may occur twice during Cycle 1, a third occurrence will require 
subject  discontinue  study  treatment . 
- During Cycle 2- 6, hold all study treatment and delay subsequent cycle until resolves 
to Grade ≤ 1. 
o If delay in cycle is requ ired but ≤ 10 days, no dose modification is required.  
 However, dose reduction of venetoclax or bendamustine is allowed per 
investigator discretion depending on attribution.  
o If delay in cycle is  >10 days, then reduce to Dose Level -1 (or D ose Level -2 if 
toxicity occ urred after Dose Level -1) of attributed drug. 
o If toxicity o ccurs at Dose Level -2 of attributed drug, subject  may dose reduce 
the other drug. 
o If toxicity occurs with venetoclax at 200 mg PO for 5 days and bend amustine 
50 mg/m2 IV day 1 and 2, subject must discontinue study treatment.  
Grade 2 Non-Hematologic 
Toxicity  
• excluding alopecia, 
nausea/vomiting, diarrhea, 
and fatigue  - During Cycle 1, hold all study treatment and resume once G rade ≤ 1. 
o Resume venetoclax  treatment and dose escalation at the dose the toxicity 
occurred. 
o There may be a prolongation of Cycle 1 by up to 2 8 days. In general, after 
resuming venetoclax, please allow for 7 (+/ - 1) days with each dose increase. 
Cycle 1 cannot be more than 49 days.  
o Re-challenge may occur twice during Cycle 1, a third occurrence will require 
subject  discontinue  study  treatment . 
- During C ycle 2 -6, if occurs at the start of a cycle, delay cycle for at least 7 days and 
up to 28 days.  Resume at same dose level when toxicity resolves to G rade ≤ 1. 
o If toxicity recurs and causes a delay in a cycle, subsequent cycles  should be 
dose reduced to Dose Level -1 of the attributed drug. 
o If toxicity occurs at Dose Level -1, modify subsequent cycles to Dose Level –2 
of the attrib uted drug. 
o If toxicity occurs at Dose Level -2 of the attributed drug, subject  may dose reduce 
the other drug. 
o If toxicity occurs with venetoclax at 200 mg PO for 5 days and bend amustine 
50 mg/m2 IV day 1 and 2, subject must discontinue study treatment.  
 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
27 - If taking venetoclax when toxicity occurs  and toxicity is attributed to venetoclax , hold 
dose until next cycle and administer without dose modification.  
o If toxicity recur s during venetoclax treatment (D ays 2 -10) and is attributed to 
venetoclax , hold venetoclax dose and reduce venetoclax next cycle to Dose 
Level -1. 
o If toxicity occurs at Dose L evel -1, modify subsequent cycles to Dose Level –2 
of venetoclax if attributed to venetoclax . 
o If toxicity o ccurs at Dose Level -2 of venetoclax , consider dose reduction of 
bendamustine. 
 
6.1.3  Tumor Lysis Syndrome Management  
Table 6- 3: Tumor Lysis Syndrome Management  
Dose Patient 
Taking When TLS 
Occurs  If Tumor Lysis Is S uspecteda Restart I nstructionsd 
Venetoclax  20 mg -Hold venetoclax  
-Strongly consider admission for IV fluids  and 
monitoring  
-Give supportive careb 
-Recheck TLS labs every 6 hours until resolvedc If TLS is absent and investigator feels safe:  
-Resume venetoclax  at 20 mg. 
-Dose escalate on schedule if no signs of TLS 
24 hours after re-dosing per protoc ol. 
Venetoclax  50 mg -Hold venetoclax  
-Strongly consider admission for IV fluids  and 
monitoring  
-Give supportive careb 
-Re-check TLS labs every 6 hours  until resolvedc If TLS is absent and investigator feels safe:  
-Resume venetoclax  at 20 mg. 
-Dose escalate on schedule if no signs of TLS 
24 hours after re-dosing per protocol . 
Venetoclax  100 mg -Hold venetoclax  
-Strongly consider admission for IV fluids  and 
monitoring  
-Give supportive careb 
-Recheck TLS labs  at least daily  until resolvedc If TLS is absent and investigator feels safe:  
-Resume venetoclax  at 50 mg. 
-Dose escalate per protocol if no signs of TLS . 
Venetoclax 200 mg  -Hold venetoclax  
-Give s upportive careb 
-Recheck TLS labs every 2-3 days until resolvedc If TLS is absent and investigator feels safe:  
-Resume venetoclax  at 100 mg. 
-Re-check TLS labs after 2 days.  
-Dose escalate per protocol if no signs of TLS . 
Venetoclax  400 mg -Hold venetoclax  for rest of cycle  
-Give supportive careb 
-Recheck TLS labs every 2-3 days until resolvedc If TLS absent and patient is not clinically 
progressing and investigator feels safe:  
-Give venetoclax  at 400 mg for subsequent 
cycle . 
-Re-check TLS labs after 2 days.  
a See Appendix IV for Definitions of Tumor Lysis Syndrome.31 
b Recommend aggressive IV and oral hydration, electrolyte management, and depending on severity, rasburicase per 
institutional standards. Depending on severity , consider hospital admission.  
c If TLS does not improve after 14 days, with good supportive care, patient  must discontinue study  treatment . 
d After a TLS event, there may be a prolongation of Cycle 1 by up to 28 days. In general, after resuming venetoclax, please allow for 7 (+/ - 1) days with each dose increase. Cycle 1 cannot be more than 49 days.  
 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
28 6.1.4 Dose Level Reductions  
Table 6- 4: Dose Modifications  for Hematologic Toxicity  
 Note that dose escalations after a dose reduction are not allowed.  
Dose Level  Venetoclax  Bendamustine  Rituximab  
0 400 mg PO daily x 10 days  90 mg/m2 IV days 1 and 2  
(70 mg/m2 if starting dose is 
such per Section 5.2.2)  No dose modifications  
-1 400 mg PO daily x 5 days  90 mg/m2 IV days 1 and 2  
(70 mg/m2 if starting dose is 
such per Section 5.2.2)  No dose modifications  
-2 400 mg PO daily x 5 days  70 mg/m2 IV days 1 and 2  
(50 mg/m2 if starting dose is 
such per Section 5.2.2)  No dose modifications  
 
Table 6-5: Dose Modifications  for Non -Hematologic Toxicity—V enetoclax  
 Note that d ose escalations after a dose reduction are  not allowed.  
Dose Level  Venetoclax  Rituximab  
0 400 mg PO daily x 10 days  No dose modifications  
-1 400 mg PO daily x 5 days  No dose modifications  
-2 200 mg PO daily x 5 days  No dose modifications  
 
Table 6-6: Dose Modifications  for Non -Hematologic Toxicity—Ben damustine  
 Note that d ose escalations after a dose reduction are  not allowed.  
Dose Level  Bendamustine  Rituximab  
0 90 mg/m2 IV day 1 and 2  No dose modifications  
-1 70 mg/m2 IV day 1 and 2 a No dose modifications  
-2 50 mg/m2 IV day 1 and 2  No dose modifications  
a 70 mg/m2 maybe the initial dose for some subjects per Section 5.2.2.  
 
6.2 Concurrent Therapies  
6.2.1  Permitted C oncurrent T herapies  
Concurrent therapy inc ludes any prescription or over -the-counter medication used 
by a patient between the 7 days preceding the study entry evaluation and the end 
of treatment/study termination visit.  
All supportive measures consistent with optimal patient care will be given 
throughout the study. Transfusion of blood products per institutional guidelines is permitted.  
Prior to Cycle 1, Day 1, s ystemic (IV or PO) c orticosteroids no greater than 1 mg/kg 
prednisone (or equivalent) given for less than or equal to 14 days will be allowed 
for treatment of lymphoma related symptoms.  While on study, systemic (IV, IM, or 
PO) corticosteroids used for non- lymphomatous conditions will be allowed; 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
29 however, systemic (IV, IM, or PO) corticosteroids will not be allowed to control 
lymphoma related symptoms after Cycle 1 Day 5.  Inhaled and topical 
corticosteroids are allowed.  
Prevention and treatment of reactions to rituximab and bendamustine  are allowed 
per intuitional standards.  
6.2.2  Not Permitted 
The use of live viral vaccines during study treatment is not allowed. Use of live viral 
vaccines within 28 days prior to the initiation of study treatment or within 30 days of the last treatment is not allowed.  
Effectiveness of inactivated vaccines, recombinant vaccines, and cell -wall vaccines 
are unreliable in NHL patients but are allowed on this protocol per treating physician discretion.  
The following treatments are prohibited from 7 days prior to initiation of treatment, during the study treatment, and within 30 da ys of the last study treatment:  
• Immunotherapy other than prescribed in the treatment plan. 
• Any FDA -approved or experimental therapy intended for the treatment of 
lymphoma including systemic corticosteroids, unless otherwise listed . 
• Warfarin (novel anticoagulants are allowed so long as there are no other drug-drug interactions) . 
• Strong to moderate inhibitors or inducers of CYP3A per Appendix III. 
o Weak inhibitors and inducers are allowed  
o Please contact PrECOG for more guidance if needed  
• Strong to moderate P-gp inhibitors such as amiodarone, azithromycin, 
captopril, carvedilol, cyclosporine, felodipine, quercetin, quinidine, ranolazine, 
ticagrelor  (Appendix III) . 
• Grapefruit and grapefruit juice, Seville oranges (including marmalade/jam) and 
star fruit are known inhibitors of CYP3A and should be avoided. 
• In cycles 2 -6 when venetoclax will not be administered (i.e., Days 11- 28), a void 
the use of strong or moderate CYP 3A inhibitors  or P-gp inhibitors 2 to 3 days 
prior to the next cycle of venetoclax treatment . 
• In cycles 2 -6 when venetoclax  will not be administered (i.e., Days 11- 28), a void 
the use of strong or moderate CYP3A inducers at least 7 days prior to the next cycle of venetoclax treatment . 
NOTE:  Continuous use of strong and moderate CYP3A inhibitors , CYP3A inducers  
or P-gp inhibitors  is not allowed. If a patient  requires continuous use of 
these drugs they will need to be excluded.  
Concomitant medications that fall into the categories below could potentially lead to 
adverse reactions and should be considered cautionary (except where noted). If a 
potential study patient is taking any of the medications in the categories described 
below, the investigator must assess and document the use of medications known or suspected to fall in the following medication categories:  
o P- gp substrates such as digoxin, everolimus, and sirolimus  due to inhibition 
potential at therapeutic dose levels . 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
30 – P-gp substrate should be avoided. If a concomitant use is unavoidable,  
separate dosing of the P- gp substrate at least 6 hours before venetoclax.  
o CYP2C8 substrates such as thiazolidinediones (glitazones) and select statins 
(because of expected inhibition of the metabolism of CYP2C8 substrates) by 
venetoclax . 
o CYP2C9 substrates such as tolbutamide (because of expected inhibition of the 
metabolism of CYP2C9 substrates by venetoclax). It is recommended to exclude CYP2C9 substrates with a narrow therapeutic index such as  phenytoin.  
Additionally, caution should be exercised, or alternative treatments considered, 
when co- administering bendamustine with a CYP1A2 inhibitor  or CYP1A2 inducer . 
Refer to Appendix III: “Additional Excluded and Cautionary Medications ” for 
additional information. 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
31 7. Study Duration and Discontinuation of Therapy 
7.1 Study Duration 
Patients will receive protocol therapy until: 
1. Any of the study drugs are permanently discontinued (i.e., Grade 4 infusion- related 
reaction with rituximab), the patient will be removed from study.  
2. Subject completes 6 cycles of treatment per Section 5.  
3. Disease progression per Lugano staging26 or clinical parameter s. 
4. Toxicities considered unacceptable by either the patient or the investigator, despite 
optimal supportive care and dose modifications . 
5. Development of an inter -current illness that prevents further administration of study 
treatment . 
6. Extraordinary Medical Circumstances: If at any time the constraints of this protocol are 
detrimental to the patient's health, protocol treatment should be discontinued.  
7. Patient withdraws consent  or is unable to comply with study procedures . 
7.2 Duration of Follow -Up 
Patients wi ll be followed for adverse events for 30 days after their last dose of study 
medication.  Patients should be followed every 3- 6 months or per institutional guidelines for 
up to 5  years from treatment dis continuation or study closure for progression and surv ival. 
Initiation of first  anti-cancer  therapy  will be documented.  
If a patient  is removed from treatment for reason(s) other than progression, follow with 
regular tumor assessments per standard of care until progr ession or start of new treatment  
with the exception of allowed maintenance rituximab. 
For patients who are registered but do not receive any protocol therapy, baseline and follow -
up information per Section 10 will be collected.  
7.3 Criteria for Removal from Study Treatment   
A genuine effort will be made to determine the reason(s) why a patient fails to return for the 
necessary visits or is discontinued from the trial, should this occur. It will be documented whether or not each patient completed the clinical study. If for any patient study treatment or observations were discontinued , the reason will be recorded on the appropriate electronic 
case report form.  Reasons that a patient may discontinue treatment  in a clinical study are 
considered to constitute one of the following:  
1. Recurrence of disease or documented progression of disease. 
2. Intercurrent illness that prevents further administration of treatment per investigator discretion.  
3. Unacceptable adverse events.  
4. Treatment interruption of more than 4 weeks  (28 days) . 
5. Investigator and/or patient decision to discontinue treatment . 
6. Pregnancy.  
7. Develops a second malignancy (except for non- melanoma skin cancer or cervical 
carcinoma in- situ) that requires treatment, which would interfere with this study . 
8. The patient may choose to withdraw  from the study at any time for any reason.  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
32 9. General or specific changes  in the patient's condition that render the patient 
unacceptable for further treatment in the judgment of the investigator.  
10. Severe non- compliance to protocol as judged by the investigat or. 
11. Lost to follow -up. 
12. Death.  
13. Closure of study by PrECOG.  
Any patient who receives at least one dose of study drug (bendamustine, rituximab or 
venetoclax ) will be included in the safety analysis. Patients who discontinue study treatment 
early should be followed for response assessments , if possible. Follow -up will continue per 
Section 10, as applicable.  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
33 8. Adverse Event Reporting 
8.1 Collection of Safety Infor mation 
Adverse Event  (AE) is defined as any new untoward medical occurrence or worsening of 
a pre- existing medical condition in a patient administered a medicinal product in a clinical 
investigation and which does not necessarily have a causal relationship with this treatment. 
An AE can therefore be any unfavorable and unintended sign (e.g., including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a product 
(investigational or marketed), whether or not considered related to the product 
(investigational or marketed).  
After informed consent, but prior to initiation of study treatment  (bendamustine, rituximab or 
venetoclax) , only AEs/SAEs caused by a protocol -mandated intervention not considered 
standard of care will be collected (e.g., SAEs related to invasive procedures such as 
biopsies). After the initiation of study treatment, all identified AEs and SAEs must be recorded and described on the appropriate page of the electronic Case Report Form 
(eCRF). If known, the diagnosis  of the underlying illness or disorder should be recorded, 
rather than individual symptoms. The following information should be documented for all AEs: date of onset and resolution, severity of the event; the investigator’s opinion of the relationship to investigational product (see definitions below); treatment required for the AE ; 
cause of the event (if known); and information regarding resolution/outcome.  
Only clinically significant laboratory abnormalities that require active management will be  
recorded as AEs or SAEs on the  eCRF (e.g., abnormalities that require  study drug dose 
modification, discontinuation of study treatment, more- frequent follow -up assessments, 
further diagnostic investigation, etc.).  
If the clinically significant laboratory abnormality is a sign of a disease or syndrome (e.g., 
alkaline phosphatase and bilirubin 5x the ULN associated with cholecystitis), only the 
diagnosis (e.g., cholecystitis) needs to be recorded on the Adverse Event eCRF.  
If the clinically significant laboratory abnormality is not a sign of a disease or syndrome, the 
abnormality itself should be recorded as an AE or SAE on the eCRF. If the laboratory abnormality can be characterized by a precise clinical term, the clinical term should be recorded as the AE or SAE. For example, an elevated serum potassium level of 7.0 mEq/L 
should be recorded as “hyperkalemia” . 
Observations of the same clinically significant laboratory abnormality from visit to visit should not be repeatedly recorded as AEs or SAEs on the eCRF  unless their severity, 
seriousness, or etiology changes.  
Severity 
The categories and definitions of severity used for clinical trials AEs are defined in the NCI’s 
Common Terminology Criteria (CTCAE) V5.0 (http://www.ctep.cancer.gov) . 
Attribution  
The following categories and definitions of causal relationship or attribution to study drug 
should be used to assess Adverse Events:  
• Definite: There is a reasonable causal relationship between the study drug and the event. 
The event response to withdrawal of study  drug (dechallenge) and recurs with 
rechallenge, if clinically feasible.  
• Probable: There is a reasonable causal relationship between the study drug and the event. The event responds to dechallenge. Rechallenge is not required.  
• Possible: There is a reasonable causal relationship between the study drug and the event. Dechallenge information is lacking or unclear.  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
34 • Unlikely: There is doubtful causal relationship between the study drug and the event.  
• Unrelated: There is clearly not a causal relationship between the study drug and the 
event or there is a causal relationship between another drug, concurrent disease, or 
circumstances and the event.  
Categories ‘definite’, ‘probable’ and ‘possible’ are considered study drug related. Categories 
‘unlikely’ and ‘unrelated’ are considered not study drug- related.  
The development of a new cancer should be regarded as an AE. New cancers are those 
that are not the primary reason for administration of study treatment and have been identified after inclusion of the patient into the clinical study.  
Expected/Unexpected : Expected AEs are those AEs that are listed or characterized in the 
Package Insert or current Investigator’s Brochure ( IB). 
Unexpected AEs are those not listed in the Package Insert  or current IB or not identified. 
This includes AEs for which the specificity or severity is not consistent with the description 
in the Package Insert  or IB. For example, under this definition, hepatic necrosis  would be 
unexpected if the Package Insert  or Investigator ’s Brochure only referred to elevated hepatic 
enzymes or hepatitis.  
Attribution and expected/unexpected should be assessed against the study drug(s) . The 
investigator will determine if event is due to bendamustine, rituximab or venetoclax, disease, etc. 
AEs related to bendamustine, rituximab or venetoclax  should be followed for 30 days 
after last dose of study therapy until ≤ grade 1 or stabilization, and reported as SAEs if they become serious.  
Any AE’s (serious or not) that occur after the above time periods but are deemed to be at least possibly related to study therapy shall be reported.  
8.2 Serious Adverse Events  
A serious AE  is any untoward medical occurrence occurring after initiation of study 
treatment or that at any dose: 
• results in death (i.e., the adverse event actually causes or leads to death)  
• is life -threatening (defined as an event in which the study patient was at risk of death at 
the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe)  
• requires inpatient hospitalization or causes prolongation of existing hospitalization  
• results in persistent or significant disability/incapacity (i.e., the adverse event results in 
substantial disruption of the subject’s ability to conduct normal life functions)  
• is a congenital anomaly/birth defect  
• is an important medical event (defined as a medical event(s) that may not be 
immediately life -threatening or result in death or hospitalization but, based upon 
appropriate medical and scientific judgment, may jeopardize the patient or may require 
intervention (e.g., medical, surgical) to prevent one of the other serious outcomes listed 
in the definition above).  
Examples of such events include, but are not limited to, intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not 
result in hospitalization.  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
35 Any suspected transmission via a medicinal product of an infectious agent is also 
considered a serious adverse reaction.  
NOTE:  Patients admitted for monitoring of tumor lysis is NOT considered an SAE.  
8.3 Adverse Events of S pecial Interest (AESI)  
The following adverse events are considered of special interest and must be reported to PrECOG as ser ious adverse events (Section 8.5  for reporting instructions), irrespective of 
regulatory seriousness criteria.  
Non Drug Specific AESIs (applicable to Venetoclax and Rituximab)  
• Drug- Induced Liver Toxicity  
Cases of potential drug- induced liver injury that include an elevated ALT or AST in 
combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law and based on the following observations:  
o Treatment -emergent ALT or AST >3x baseline value in combination with total 
bilirubin >2x ULN (of which >35% is direct bilirubin)  
o Treatment -emergent ALT or AST >3x baseline value in combination with clinical 
jaundice  
Criteria for Hy’s Law (FDA G uidance 2009)  
- The drug causes hepatocellular injury, generally shown by a higher incidence 
of 3- fold or greater elevations above the ULN  of ALT or AST than the 
(non- hepatotoxic) control drug or placebo. 
- Among trial subject s showing such aminotransferase elevations, often with 
aminotransferases  much greater than 3x ULN, one or more also show elevation  
of serum total bilirubin to >2x ULN, wi thout initial findings of cholestasis 
(elevated serum alkaline phosphatase) . 
- No other reason can be found to explain the combination of increased 
aminotransferases and total bilirubin, such as viral hepatitis A, B, or C; pre-
existing or acute liver disease; or another drug capable of causing the observed injury.  
• Suspected transmission of an infectious agent by the study treatment, as defined below : 
o Any organism, virus, or infectious particle (e.g., prion protein transmitting transmissible spongiform encephalopathy), pathogenic or non- pathogenic, is 
considered an infectious agent. A transmission of an infectious agent may be suspected from clinical symptoms or laboratory findings that indicate an infection in a patient exposed to a medicinal product. This term applies only when a 
contamination of study treatment is suspected. 
Venetoclax Events of Special Interest  
• Any grade tumor lysis syndrome (TLS) 
o Definitions for TLS is described in Appendix IV: “Definition of Tumor Lysis 
Syndrome”31. Please note that, if the clinical scenario fits for TLS, use these criteria 
for evaluating renal and electrolyte imbalances occurring at the same time.  
- Laboratory TLS  (2 or more metabolic abnormalities present)  = Grade 3  
- Clinical TLS (laboratory TLS must also be present)  = Grade 4  
- Fatal = Grade 5  
Rituximab Events of Special Interest  
• None  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
36 8.4 Special Situation Reports  
8.4.1  COVID -19 Reporting  
All positive COVID -19 test results must be reported with the type of test performed 
recorded. 
Coding for COVID -19 adverse events will be as follows.  
• Infections and infestations - Other, specify  
• Specify = COVID -19 
The categories and definitions of severity used for COVID -19 AEs are defined in 
NCI’s CTCAE V5.0 (http://www.ctep.cancer.gov ). 
COVID -19 adverse events that qualify as Serious Adverse Events per Section 8.2 
must be reported as such, per Section 8.5.  The following information will be 
captured:  
• Narrative: Identify all pertinent facts related to the COVID -19 infection 
including, but not limited to the following: Presumptive vs confirmed diagnosis. 
If presumptive, please update narrative if/when diagnosis is confirmed, 
including timelines.  
- Treatment information  
- Recovery information, including timelines  
- Outcome information/status  
All deviations or wi thdrawals due to COVID -19 will documented as such in the 
eCRF.  
8.4.2  Other  
In addition, the following Special Situation Reports should be collected  and reported 
to PrECOG on a PrE0405  SAE Form  even in the absence of an AE  and PrECOG 
will transmit to Genentech within thirty (30) calendar days : 
● Data related to the product usage during pregnancy or breastfeeding (Section 
8.7). 
● Data related to overdose, abuse, misuse, error (including potentially exposed 
or intercepted medication errors) . 
- For any symptomatic overdose, even if not fulfilling a seriousness 
criterion , a SAE f orm should be completed and reported to PrECOG  
within 24 hours of the investigator ’s knowledge of the overdose.  
● Data related to a “suspected transmission of an infectious agent via a medicinal product . 
8.5 SAE Reporting Requirements  
Serious adverse events (SAE) are defined above. The investigator should inform PrECOG of any SAE within  24 hours of being aware of the event. The date of awareness should be 
noted on the report. This must be documented on the PrECOG SAE form. This form must be completed and supplied to PrECOG within 24 hours/1 business day at the latest on the 
following wor king day . The initial report must be as complete as possible, including details 
of the current illness and (serious) adverse event, and an assessment of the causal relationship between the event and the investigational product(s). Information not available at the time of the initial report (e.g., an end date for the adverse event or laboratory values 
received after the report) must be documented on a follow -up PrECOG SAE report form. A 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
37 final report to document resolution of the SAE is required.  The investigator is responsible 
for following all SAEs until resolution, until the subject returns to baseline status, or until the 
condition has stabilized with the expectation that it will remain chronic, even if this extends beyond study participation.  A copy of t he email of the SAE report to PrECOG should be 
attached to the SAE and retained with the patient records.  
SAEs  should be  scanned and emailed to PrE0405SAE@qdservices.com  as per the 
instructions found in study  materials provided to the investigator site. 
 
Medical Monitor  
During normal business hours  
(8:30 am -5:00 pm EST):  
Phone: 610- 354-0404 
After normal business hours:  
Phone:  484-574-2367 
Email:  Manager,  Clinical Safety  
During normal business hours  
(8:30 am -5:00 pm EST):  
Phone: 610- 354-0404 
After normal business hours:  
Cell: 484-574-2367  
PrECOG will notify Genentech of any SAE’s and AEs of Special Interest (regardless of 
causality) within 1 business day  of the Awareness Date. All non- serious adverse events will 
be provided to Genentech quarterly. Relevant follow -up information will be provided to 
Genentech as soon as it becomes available.  
Investigators should also report event(s) to their IRB as required.  
Collection of complete information concerning SAEs is extremely important. Full 
descriptions of each event will be followed. Thus, follow -up information which becomes 
available as the SAE evolves, as well as supporting documentation (e.g., hospital discharge 
summaries  and autopsy reports), should be collected subsequently, if not available at the 
time of the initial report, and immediately sent using the same procedure as the initial SAE 
report.  
All SAEs, regardless of causality, must be collected which occur within 30 days of last dose 
of study treatment. This includes all deaths within 30 days of  last dose of bendamustine, 
rituximab or venetoclax  regardless of attribution. In addition, the Investigator should notify 
PrECOG or designee of any SAE that may occur after this time period which they believe to be definitely, probably or possibly related to investigational product . 
NOTE:  After study closure, study -drug related SAEs should be reported voluntarily by the 
treating physician to the manufacturer . 
Serious adverse event reporting to regulatory authorities and all participating investigators 
will be conduc ted by PrECOG  (or designee) in accordance with 21CFR312.32, local 
requirements  and international regulations, as appropriate.  FDA reporting requirement 
timelines will be followed.  PrECOG will also concurrently forward any such reports to 
Genentech.  
8.6 Product Complaints  
A Product Complaint is defined as any written or oral information received from a complainant that alleges deficiencies related to identity, quality, safety, strength, purity, reliability, durability, effectiveness, or performance of a product after it has been released 
and distributed to the commercial market or clinical trial.  
Product Complaints (with or without an AE) for venetoclax originating from the Study will be 
collected and reported to PrECOG on a PrE0405 Product Complaint  Reporting Form even 
in the absence of an AE  (if product complaint is an SAE, the PrE0405 SAE form will also be 
completed) . PrECOG will transmit product complaints to Genentech for venetoclax within 
fifteen (15) calendar days. Product complaints for bendamustine and rituximab will be reported per each sites standard procedures.  

PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
38 8.7 Reporting of Other Second Primary Cancers  
New cancers are those that are not the primary reason for administration of study treatment 
and have been identified after inclusion of the patient into the clinical study.  
All cases of new primary cancers  that occur during or after protocol treatment must be 
reported to PrECOG  on a Second Primary Cancer  form within 30 days of diagnosis, 
regardless of relationship to protocol treatment. Secondary primary malignancies should also be reported as a SAE. The SAE form is not for use for reporting recurrence or development of metastatic disease. A copy of the pathology report, if applicable, should be sent, if available.  
NOTE : Once data regarding survival and remission status are no longer required by the protocol, no follow -up data should be submitted.  
8.8 Procedures in Case of Pregnancy  
Prior to study enrollment, women of childbearing potential (WOCBP) and male patients with a female partner of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional 
pregnancy, documented in the informed consent. In addition, all WOCBP should be instructed to contact the Investigator immediately if they suspect they might be pregnant (e.g., missed or late menstrual period) at any time during study partic ipation.  
Pregnancy of a female patient or the female partner of a male patient  occurring whil e the 
patient is receiving study drug or within 12 months  after the patient’s last dose of study drug 
will be reported to PrECOG  on a Pregnancy Form within 24 hours of the investigator’s 
knowledge of the pregnancy.  
All reports of congenital abnormalities/birth defects and spontaneous miscarriages should also be reported and handled as SAEs. Elective abortions without complications should not be handled as AEs.  
The outcome of all pregnancies (spontaneous miscarriage, elective termination, normal birth including health of the newborn or congenital abnormality) must be followed and 
documented on the Pregnancy Form even if the subject was discontinued from the study 
treatment. Should pregnancy occur during a subject’s participation, the subject will immediately be discontinued from the treatment and followed per protocol.  
The study -specific Pregnancy F orm can be found in the Study Reference Manual.  
PrECOG will notify Genentech of any pregnancy within 1 business day of the Awareness 
Date.  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
39 9. Measurement of Effect  
9.1 Response A ssessments  
Patients  should have a baseline PET/CT.  Repeat imaging in the form of CT or PET/CT 
before Cycle 3 or 4 should be done per institution guidelines. End of treatment PET/CT 
should be performed 6- 8 weeks after the final cycle of therapy  (6-8 weeks after Cycle 6 Day 
1) and is the primary endpoint for this study. Bone marrow biopsy and aspiration will be 
perfor med at the end of treatment when it is  standard of care. 
Any progression on therapy should be confirmed with PET/CT.  
After the End of treatment PET/CT, all other imaging will be per institution standards. 
Patients  will be followed until progression or for up to 5 years  from treatment discontinuation 
or study closure. 
9.2 Lymphoma Response Criteria (Lugano Classification)32 
Response and progression will be evaluated in this study using international criterial 
proposed by the 11th International Conference on Malignant Lymphoma in Lugano 
Switzerland (Lugano Classification).32 
The criteria use Complete Response (CR), Partial Response (PR), Stable disease (SD) or 
Progressive Disease (PD) to evaluate response.  PET/CT is the primary modality to measure 
response and will be utilized for the primary outcomes; however, CT without PET component may be adequate at other measurements.  
Tumor measurements will be recorded at baseline for at least 6 dominant nodes or 
extranodal masses. If there are less than 6 measurable lesions, all lesions must be measured and followed. Selection of masses to follow should maintain that they are clearly measurable in 2 perpendicular directions, and should be from different regions of the body whenever possible. Measurements should be in centimeters to the nearest one tenth and 
in two planes, one being the longest diameter and the other its perpendicular counterpart.  
Measurements of lesions will be done at baseline and at each disease assessment.  
Non- target lesions can be utilized also. These may be dominant lesions over 6 nodes 
identified or lesions which are seen but difficult to measure (i .e., a bone lesion with FDG 
activity bu t no clearly defined borders). Non-target lesions will be recorded as present or 
absent.  
Spleen size, in cranio- caudal cross sectional measurement, should be recorded at each 
disease assessment.  
Full criteria can be found in Appendix V: Revised Criteria for Response Assessment .
32 
End of treatment PET/CT is the primary response assessment. A 5-point scale, also known 
as the Deauville criteria, (Table 9-1) should be utilized to measure FDG uptake and 
treatment response via PET. Each target lesion should have a Deauville score at the end of treatment.
33 
 
    
 
 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
40  
   
 
    
 
9.2.1 C omplete  Response Definition 
CR rate per Lugano criteria, utilizing the PET/CT criteria listed in Appendix V, is the 
primary outcome for this study. It is defined as a complete metabolic response via PET/CT as well as a morphologically negative bone marrow biopsy and aspiration. Bone marrow flow cytometry should not be utilized in CR assessments . If bone 
marrow biopsy and aspiration was not involved by MCL at screening, a repeat bone marrow biopsy and aspiration is not required to assess CR status (PET/CT imaging alone will suffice).  
All other responses, including PR, SD, PD and CT based criteria  are indicated 
in the Lugano Criteria, listed in A ppendix V  Revised Criteria for Response 
Assessment.
32 
9.3 Minimum Residual Disease (MRD) Measurements  
MRD negative rate at the end of treatment assessment are exploratory endpoints in this study. MRD will be measured using PCR based markers through Adaptive  Biotechnologies 
(clonoSEQ ) on tumor tissue (baseline only), liquid marrow aspirate  and peripheral blood 
samples . 
Baseline tumor tissue sample will be obtained. If tumor tissue is not available, bone marrow 
aspirate or peripheral blood may be substituted , if involved with mantle cell lymphoma,  for 
baseline comparison sample.  If baseline samples (blocks/slides, bone marrow, and/or 
peripheral blood) are not submitted at baseline for MRD  (i.e., not involved with mantle cell 
lymphoma) , then patients will be allowed to remain on study but MRD samples will not be 
collected during the study.  
Bone marrow aspirate for MRD testing will be collected  at the end of treatment  per standard 
of care. Please note,  if bone marrow is positive for mantle cell lymphoma at baseline, an 
end of treatment bone marrow must  be collected to confirm response.  
Peripheral blood for MRD assessments will be collected at the end of treatment.  
 Table 9- 1: Deauville Criteria for Target and Non -Target L esions 
Score  Criteria  
1 No uptake 
2 Uptake less than or equal to the mediastinal blood pool  
3 Uptake greater than the mediastinal blood pool but less than the liver  
4 Uptake moderately higher than the liver  
5 Uptake markedly higher than the liver and/or new lesions  
X Areas of uptake unlikely to be related to lymphoma 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
41 10. Study Treatments, Parameters , and Assessments  
1. All pre -study scans and biopsies  should be done ≤ 6 weeks prior to registration.  
2. All other pre- study assessments should be done ≤ 2 weeks prior to registration, unless otherwise noted . 
Procedures  Screening  Cycle 1 * 
(1 cycle=28 Days)  Cycle 2 and Subsequent 
Cycles* Prior to 
Cycle 3 
or 4 End of  
Treatment 
Visit25 Follow -Up27 
Day 
1 Day 
2 Day 
8 Day 
15 Day 
22 Day 
1 Day 
2 Day 
10 Day 
11-28 
Windows (+/ - days):  -28 to -1  1 1 1 1 3 1   7 14  
Administrative Procedures  
Written Informed Consent  X             
Disease Characteristics1 X             
Medical/Surgical History  X             
Assessment of Baseline Signs 
& Symptoms  X             
Prior and Concomitant 
Medication Review  X X     X     X  
Clinical Procedures/Assessments  
Height  X             
Physical Exam including Weight  X X     X     X  
Vital Signs  
(Temperature, Pulse, Blood 
Pressure) X X X X X X X    
 X  
Body Surface Area (BSA)  X X     X       
ECOG Performance Status  X X     X     X  
Review Adverse Events   X  X X X X     X26  
Laboratory A ssessments  
CBC/Differential/Platelets2 X X  X X X X     X  
Chemistry3 X X X X X X X X4    X  
Liver Function5 X X     X     X  
LDH X           X  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
42 Procedures  Screening  Cycle 1* 
(1 cycle=28 Days)  Cycle 2 and Subsequent 
Cycles* Prior to 
Cycle 3 
or 4 End of  
Treatment 
Visit25 Follow -Up27 
Day 
1 Day 
2 Day 
8 Day 
15 Day 
22 Day 
1 Day 
2 Day 
10 Day 
11-28 
Windows (+/ - days):  -28 to -1  1 1 1 1 3 1   7 14  
Tumor Lysis Labs6  X X X X X X X4      
Beta-2 Microglobulin  X           X  
Hepatitis B and C Testing7 X             
Serum Pregnancy Test8 X             
CMV Monitoring9 X      X     X9  
Treatments10 
Oral Hydration11  X X X X X X11       
Intravenous Hydration12  X     X12       
Venetoclax (dose in mg)13  20 20 50 100 200 400 400 400 0    
Bendamustine14  X X    X X      
Rituximab15  X     X       
Growth Factor Support16   X     X      
PJP & Antiviral Prophylaxis17       X X X X  X  
Subject Calendars  
Venetoclax Medication Diary   X X X X X X X X     
Disease Assessments/Measurements  
PET/CT  X           X18  
Bone Marrow Biopsy & Aspirate  X           X19  
CT Chest/Abdomen/Pelvis            X20   
Disease and Survival Status            X X X 
Correlative Study Samples  
Archived Tissue Procurement  
(Mandatory)21 X           X22 X22 
Research Blood Specimens  
(Optional)23  X     X23     X  
MRD testing24 
(Mandatory)  X          
 X  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
43 * Scheduled Visits:  In general +/- 3 day window for therapy/ tests/visits  during therapy  except as noted for TLS monitoring . Delay due to holidays, weekends, 
bad weather or other unforeseen circumstances will be permitted. 
1 Record date of diagnosis, primary tumor type, histology, stage, and MCL international prognostic index  (MIPI ). MIPI calculator can be accessed using the  
website at  https://qxmd.com/calculate/calculator_149/mipi -mantle -cell-lymphoma-prognosis34 or https://www.mdcalc.com/mantle -cell-lymphoma-
international -prognostic -index -mipi35.36,37 
2 CBC with differential and platelet count which includes WBC, ANC, Platelets, Hgb, and Hct.  Required prior to each dose of  treatment , and results known prior 
to treatment administration. 
3 BUN/ creatinine, sodium, potassium, chloride, bicarbonate (HCO 3), glucose, and calcium . Refer to Section 5.4 , Table 5-3 “Tumor Lysis Monitoring” for 
additional time points and days not captured on Study Calendar.  
4 Cycle 2, Day 2 only.  
5 Albumin, total protein, alkaline phosphatase, AST, ALT,  and total bilirubin. 
6 Basic Metabolic Panel (Sodium, Potassium, Chloride, Bicarbonate (HCO3), BUN, Creatinine, Calcium), Albumin, Uric Acid, and Phosphorus . Refer to  Section 
5.4, Table 5- 3 “Tumor Lysis Monitoring” for additional time points and days not captured on Study Calendar . See Appendix IV for “Definitions of Tumor Lysis 
Syndrome31”. 
7 H epatitis B  (HBV), H epatitis B surface antigen (HBsAg), and Hepatitis C (HCV) testing within 6 weeks of registration . Patients who are chronic carriers of HBV 
with positive HBsAg+ and  positive HCV serology  are excluded. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core 
antibody [anti -HBc] and absence of HBsAg)  are allowed with protective hepatitis B surface antibody AND a negative hepatitis B viral load by PCR. If enrolled, 
patients must be willing to undergo monthly HBV DNA testing.  
Patients with positive HCV antibody must be negative for HC V by PCR  to be eligible for study participation.  Prior treatment for an active hepatitis C infection 
will be allowed so long as the hepatitis C viral load by PCR is negative.  
8 Required for females of child- bearing potential.  
9 Patients will be monitored for CMV reactivation using Quantitative PCR Assay for CMV DNA. If CMV PCR is reported as >137 IU/mL increa se frequency of 
testing to weekly. See Section 5.7: Monitoring for Cytomegalovirus (CMV) for additional monitoring parameters and guidelines.  
Induction:  Once a month and end of induction . 
Maintenance:  Treating physician discretion or per institutional standards ; however, if detectable, recommend continued monitoring per institutional standards . 
10 Standard pre-medications  and antiemetic therapy per institutional guidelines  are allowed per Section 5.1. Also, refer to Section 5.3 for details on prophylaxis 
for TLS.  
11 Encourage at least  2 liters of or al fluids per day starting 24 hours prior to Cycle 1, Day 1 and continuing until Cycle 2, Day 10.  Refer to Section 5.3 for details . 
12 At least 1 liter of IV hydration should be given on Day 1 of Cycle 1 and Cycle  2. Additional IV fluids and monitoring for TLS is allowed per treating physician 
discretion.  Refer to Section 5.3 for details . 
13 Venetoclax will be administered orally. Cycle 1:  20 mg on Day 1 -7; 50 mg on Day 8-14; 100 mg on Day 15 -21; and 200 mg on Day 22- 28. Cycle 2-6:  400 mg 
on Day 1-10.  One cycle = 28 days . On days when venetoclax is given with additional anti-lymphoma agents, venetoclax should be given first.  See Section 5 
for dosing instructions  and tumor lysis prophylaxis/monitoring  and Section 6 for dose delays/modifications.  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
44 14 Bendamustine is given as 90  mg/m2 IV day 1 and 2 before or after rituximab. See Section 5 for dosing instructions and Section 6 for dose delays/modifications.  
NOTE:  Per investigator discretion, bendamustine may be started at 70 mg/m2 in patients over the age of 75 years with comorbid conditions or patients over 
the age of 80 years without comorbid conditions.  
15 Rituximab 375 mg/m2 is given  on Day 1 of each cycle before or after bendamustine . If the first two cycles  (or two consecutive cycles)  of rituximab are well 
tolerated, IV rituximab may be replaced with 1400 mg/23,400 units SQ rituximab/hyaluronic acid on Day 1 of Cycles 3-6 (or after 2 consecutive cycles are 
well tolerated), per investigator and patient preference. Biosimilars for rituximab are permitted. See Section 5 for dosing instructions and Section 6 for dose 
delays/modifications.  
NOTE:  After 6 cycles of venetoclax, bendamustine and rituximab, subjects responding to therapy may receive maintenance rituximab (one dose every 8 ± 
2 weeks for 12 doses or 24 months  whichever comes first ) per physician and patient preference.  
16 Growth factor support should be given 24-72 hours after the last dose of bendamustine for  each cycle per Section 5.5. 
17 All patients must be initiated on prophylaxis at the start of Cycle 2 of  venetoclax, bendamustine and rituxi mab.  
PJP Prophylaxis:  Trime thoprim -sulfamethoxazole (Bactrim) for PJP prophylaxis and should continue until 6-8 weeks from Day 1 of last completed induction 
cycle . PJP prophylaxis may be discontinued at that time, or continued at the discretion of the treating physician.  
Antiviral Prophylaxis:  Acyclovir or valcyclovir for antiviral prophylaxis. Antiviral prophylaxis should continue for a minimum of 6 months after completion of 
induction, and may be discontinued at that  time, or continued at the discretion of the treating physician.  
See Section 5.6: Infection Prophylaxis for additional parameters and guidelines.  
18 PET/CT 6 -8 weeks after Day 1 of last completed cycle. Each target lesion should have Deauville score at end of tre atment. Refer to Section 9.2,  Table 9-1 
and Appendix V  for details.  
19 Bone marrow biopsy and aspirate per standard of care but must be performed if PET/CT shows CR and bone marrow biopsy was positive at screening to 
confirm CR . Mandatory sample submission for research when collected per standard of care.  
20 Repeat imaging before Cycle 3 or 4 per institutional guidelines. CT scans or PET/CT scans may be used at this time point per institution standards. Any 
progression should be confirmed by PET/C T. 
21 Pre-treatment, diagnostic pathology specimens  (organ or lymph node biopsy or excision) obtained in the course of standard biopsy or surgery  (if sufficient 
tissue is available, submission is mandatory) . Formalin -Fixed Paraffin -Embedded (FFPE)  blocks and 5 FFPE slides or up to  15 FFPE  slides  plus H&E slide  
(if tiss ue is limited, then minimum of 10  slides ) will be required. Procurement of tissue will be mandatory for enrollment, but if additional tissue from initial 
biopsy is not available,  repeat biopsy will not be required. Optional:  Any leftover tissue banked for future research. See Section 13. 1 and PrE0405 Lab Manual 
for details.  
NOTE:  If block s and/or slides are unavailable  and bone marrow is involved with mantle cell lymphoma, obtain two 2 mL EDTA tubes of bone marrow aspirate 
(one for baseline MRD analysis  and one for future research). If blocks/slides and bone marrow are unavailable and peripheral blood is involved with 
mantle cell lymphoma obtain one 4 mL and one 6 mL EDTA tubes of peripheral blood (one for baseline MRD analysis and one for future research) . 
If baseline samples (blocks/slides, bone marrow, and/or peripheral blood) are not submitted at baseline for MRD  (i.e., not involved with mantle cell 
lymphoma) , then patients will  be allowed to remain on study but MRD samples will not be collected during the study.  
22 Optional:  At time of  progression, biopsy samples are requested to be sent for correlative studies  and banked for future research.  See Section 13.1 and 
PrE0405 Lab Manual for details.  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
45 23 Optional  Research Bloods : See Section 13.3 and PrE0405 Lab Manual for details.  
Cycle 1, Day 1 (prior to treatment ) 
Peripheral Blood: One 10 mL red top tube and one 6 mL in EDTA tube 
Cycle 2, Day 1 (prior to treatment)  
Peripheral Blood: One 10 mL red top tube and one 6 mL in EDTA tube 
Cycle 4, Day 1 (prior to treatment ) 
Peripheral Blood: One 10 mL red top tube and one 6 mL in EDTA tube 
End of Treatment Visit  
Peripheral Blood: One 10 mL red top tube and one 6 mL in EDTA tube 
At Time of Progression  
Peripheral Blood: One 10 mL red top tube, one 4 mL and one 6 mL in EDTA tube  
24 Mandatory MRD S amples:  See Section 13.1, 13.2, 13.3 and PrE0405 Lab Manual  for details . 
Screening/Study Entry  
FFPE: 3 -5 FFPE slides  from lymph node (preferred)  
NOTE:  If FFPE unavailable, either bone marrow aspirate  (2 mL EDTA tube)  or peripheral blood (4 mL EDTA tube) are acceptable  as long as they are 
involved with mantle cell lymphoma.  If baseline samples (blocks/slides, bone marrow, and/or peripheral blood) are not submitted at baseline for MRD  
(i.e., not involved with mantle cell lymphoma), then patients will be allowed to remain on study but MRD samples will not be collected during the 
study.  
End of Treatment  Visit 
Peripheral Blood: One  4 mL in EDTA tube  
Bone Marrow  Aspirate (per standard of care) *: One  2 mL in EDTA tube 
*Bone Marrow Aspirate: Submission is  mandatory when collected per standard of care.  Please note,  if bone marrow is positive for mantle cell lymphoma at 
baseline, an e nd of treatment bone marrow must  be collected to confirm response.  
25 6-8 weeks  after D ay 1 of last completed cycle. 
26 Patients will be followed for adverse events for 30 days after their last dose of study medication . 
27 Every 3 -6 months or per institutional guidelines for up to 5 years from treatment disco ntinuation for progression and survival . Imaging to be done per institution 
standar ds and/or physician discretion.  Maintenance rituximab is allowed and will be documented but will not constitute additional therapy. Initiation of first 
anti-cancer therapy  will also be documented.  
NOTE:  If patient is removed from treatment for reason(s) other than progression, follow with regular tumor assessments per standard of care until progression 
or start of new treatment  with the exception of allowed maintenance rituximab for up to 5 years or study closure.  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
46 11. Drug Formulation and Procurement  
11.1 Venetoclax21,22 
11.1.1  Other Names  
GDC- 0199, ABT -199, RO5537382. 
11.1.2  Classification  
Oral Bcl-2 fami ly protein inhibitor.  
11.1.3  Storage and Stability  
Venetoclax will be supplied in bottles with 10 mg, 50 mg, and 100 mg tablets.  
The 10 mg film -coated tablets are round, biconvex shaped, pale yellow debossed with 
“V” on one side and “10” on the other side.  
The 50 mg film -coated tablets are oblong, biconvex shaped, beige debossed with “V” 
on one side and “50” on the other side.  
The 100 mg film-coated tablets are oblong, biconvex  shaped, pale  yellow debossed  
with “V” on one side and “100” on the other side.  
The tablets must be stored at 15 °C−25°C (59°F−77°F). 
11.1.4  Dose Specifics  
In Cycle 1, venetoclax is dispensed in a 1- week supply. There will be a gradual dose 
escalation in Cycle 1 (Table 5- 2). 
In Cycle 2- 6, venetoclax  is dispensed in a 4- week supply. Cycle 2- 6, patients will take 
four tablets (400 mg) daily on days 1- 10 for each 28 day cycle . Tablets should not be 
chewed, crushed or broken.  
On days when venetoclax is given with bendamustine and rituximab, venetoclax 
should be given first.  
If vomiting occurs within 15  minutes after taking venetoclax and all expelled tablets are 
still intact, another dose may be given . Otherwise, no replacement dose is to be given.  
If patient misses a dose of venetoclax  within 8 hours of when it is usually taken, the 
patient should take the dose as soon as possible and resume normal daily dosing schedule. Should the dose be missed by greater than 8 hours, the dose should be skipped and patient should resume normal daily dosing the following day. This dose should not be made up. 
Refer to Section 5.2 for  details.  
11.1.5  Drug Interactions  
Drug- drug interactions may occur with venetoclax. Co-administration of venetoclax 
with strong to moderate inhibitors or inducers of CYP3A  or P-gp inhibitors  is prohibited. 
Co-administration with weak CYP3A inhibitors and inducers  is allowed . P-gp substrate 
should be avoided. If a concomitant use is unavoidable, separate dosing of the P -gp 
substrate at least 6 hours before venetoclax.  
In cycles 2- 6 when venetoclax will not be administered (i.e., Days 11- 28), avoid the 
use of strong or moderate CYP3A inhibitors or P -gp inhibitors 2 to 3 days prior to the 
next cycle of venetoclax treatment. Also avoid the use of strong or moderate CYP3A 
inducers at least 7 days prior to the next cycle of venetoclax treatment.  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
47 See Section 6.2.2  and Appendix III: Additional Excluded and Cautionary Medications  
for a list of medications that are to be excluded or used with caution in patients 
receiving venetoclax.  
11.1.6  Availability 
Venetoclax  will be s upplied  by Genentech. 
The initial supply of venetoclax  will be sent directly to the site upon site activation. As 
needed,  venetoclax may be requested by the Principal Investigator (or their authorized 
designees) at each participating institution. The investigator, or a responsible party 
designated by the investigator, must maintain a careful record of the receipt, disposition, and return/destruction (site’s drug destruction policy must be reviewed and 
approved by PrECOG before any study drug can be destroyed at a site) of venetoclax . 
11.1.7  Agent Ordering  
PrECOG will be responsible for ordering drug for re- supply to the site. Requests for 
shipments of venetoclax  will be coordinated between PrECOG and Genentech.  
11.1.8  Agent Accountability  
Venetoclax will be stored in a secure location. Only authorized pharmacy and study 
staff will have access to this agent. Drug accountability will be performed by PrECOG.  
Please refer to the current Investigator’s Brochure for additional information.  
11.1.9  Side Effects  
11.1.9.1  Tumor Lysis Syndrome 
TLS is a risk for patients with MCL  who are treated with high cell -killing 
agents, including venetoclax. The highest risk for TLS occurs within the first 
24 hours of a dose escalation caused by rapid reduction of the tumor . Refer 
to Section 5.3 for Tumor Lysis Prophylaxis and Section 5.4 for Tumor Lysis 
Monitoring. 
NOTE : Defined risks for TLS are not clear in MCL but some higher risk 
situations include:  
 Bulky disease (any lymph node mass >10 cm)  
 Circulating mantle cell lymphoma with ALC >25 x 10
9/L 
 Borderline renal function  
 Rapidly progressing disease.  
11.1.9.2  Neutropenia  
Neutropenia is an important identified risk for venetoclax, specifically in CLL. 
Clinical data from the oncology studies suggest that the neutropenia adverse events are observed among subjects who receive venetoclax as a single agent or in combination with other therapeutic agents, with slightly higher frequency observed in some combination studies. Serious adverse events of neutropenia or neutropenia events that lead to discontinuations 
are few across the entire venetoclax oncology program.  
11.1.9.3  Infections  
Infections have been reported in the oncology clinical studies; however, 
these events are confounded by the underlying disease, comorbidities, an d 
other immunosuppressive medications. To date, no clear relationship has 
been noted between serious infectious events and neutropenia. The types 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
48 of infectious events observed generally have been consistent with those 
anticipated in the elderly population of heavily pretreated subjects with hematologic malignancies and are similar across all indications.  
Infections should be closely monitored in this study. Recommendations for 
anti-infective prophylaxis are per standard of care (e.g., National 
Comprehensive Cancer Network guidelines [NCCN] for oncology subjects).  
11.1.9.4  Anemia  
Anemia has been reported in the oncology studies with slightly higher 
frequency in some studies in which venetoclax is combined with other chemotherapeutic agents; however, most of the events were nonserious 
and confounded by disease factors and prior therapies.  
11.1.9.5  Thrombocytopenia  
Thrombocytopenia adverse events have been reported in the oncology 
studies, with slightly higher frequency in studies in which venetoclax  is 
combined with other chemotherapeutic agents.  However, most of the events 
were nonserious and assessment of these events is confounded by the patients’ underlying disease states, prior therapies, and preexisting thrombocytopenia, including autoimmune thrombocytopenia, in several patients.  
11.1.9.6  Lymphopenia  
Lymphopenia has been observed in nonclinical studies with venetoclax. 
While opportunistic infections have been reported in the clinical program, 
data are confounded by patients’ underlying disease and prior therapies.  
If clinically indicated, anti -infective prophylaxis should be implemented, 
including appropriate prophylaxis for viral, fungal, bacterial, or 
Pneumocystis  jiroveci  pneumonia infections.  
11.1.9.7  Reproductive System Effects  
Based on nonclinical studies, there is a potential for decreased spermatogenesis. Male patients considering preservation of fertility should bank sperm before treatment with venetoclax. Long- term effects of 
venetoclax on female reproductive potential are unknown.  
11.1.9.8  Treatment -Emergent Malignancies (Second Primary Malignancies)  
Events of second primary malignancies have been reported across the oncology program. No pattern has been was observed. As venetoclax is being evaluated in patients with relapsed/refractory  (R/R) disease who had 
previously been treated with various cytotoxic agents, second primary malignancies should be closely monitored.  
11.1.9.9  Food Effect  
Administration with a low-fat meal incr eased venetoclax exposure by 
approximately 3.4-fold an d administration with a high-fat meal incr eased 
venetoclax exposure by 5.1- to 5.3-fold compare d to fasting conditions . 
Vene toclax sh ould be administered with a mea l. 
 
 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
49 11.1.9.10  Drug- Drug Interaction  
Co-administration of venetoclax with strong to moderate inhibitors or 
inducers of CYP3A  or P-gp inhibitors  is prohibited . Co- administration with 
weak CYP3A inhibitors and inducers  is allowed.  P-gp substrate should be 
avoided. If a concomitant use is unavoidable, separate dosing of the P -gp 
substrate at least 6 hours before venetoclax.  
In cycles 2- 6 when venetoclax will not be administered (i.e., Days 11- 28), 
avoid the use of strong or moderate CYP3A inhibitors or P -gp inhibitors 2 to 
3 days prior to the next cycle of venetoclax treatment . Also avoid the use of 
strong or moderate CYP3A inducers at least 7 days prior to the next cycle 
of venetoclax treatment.  (Section 6.2.2 and Appendix III: Additional 
Excluded and Cautionary Medications ). 
Live attenuated vaccines should not be administered prior to, during, or 
after treatment  with venetoclax until B -cell recovery occurs.  
11.1.9.11  Overdose  
There is no specific  antidote for venetoclax . For patients  who experience 
overdose,  closely  monitor  and provide appropriate supportive treatment;  
during ramp- up phase interrupt  venetoclax  and monitor carefully  for signs  
and symptoms  of TLS along with other toxicities . 
11.1.10  Nursing/Patient Implications  
1. TLS: Inform patient to immediately  report  any signs  and symptoms  associated with 
TLS (fever,  chills,  nausea,  vomiting,  confusion,  shortness of  breath,  seizure,  
irregular heartbeat,  dark or cloudy  urine, unusual tiredness,  muscle pain, and/or 
joint discomfort) to their doctor.  
2. Neutropenia:  Monitor  blood  counts  and for signs of infection; manage as  medically  
appropriate.  
3. Advise patients  to avoid consuming  grapefruit  products,  Seville oranges,  or starfruit  
during treatment  with venetoclax.  Advise patients  to inform  their doctor of the use 
of any prescription medication,  over-the-counter drugs,  vitamins  and herbal  
products.  
11.2 Bendamustine38 
Bendamustine will be obtained by the individual study sites as standard of care treatments 
from commercial stock. Refer to commercial package inserts for full prescribing information.  
11.2.1  Other Names  
Bendamustine hydrochloride, Treanda, Bendeka. 
11.2.2  Classification  
Alkylating neoplastic agent.  
11.2.3  Storage and Stability  
Bendamustine for injection,  is supplied in multiple -dose vials containing 100 mg of 
bendamustine hydrochloride as a clear, and colorless to yellow ready -to-dilute 
solution. Store intact vials in refrigerator, 2° -8°C (36°- 46°F) . Vials should be retained 
in the original package until time of use to protect from light.  
Admixture Stability: Bendamustine contains no antimicrobial preservative. The 
admixture should be prepared as close as possible to the time of patient administration. 
Once diluted with either 0.9% Sodium Chloride Injection, USP, or 2.5% 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
50 Dextrose/0.45% Sodium Chloride Injection, USP, the final admixture is stable for 24 
hours when stored refrigerated (2- 8°C or 36- 47°F) or for 6 hours when stored at room 
temperature (15- 30°C or 59- 86°F) and room light. Administration of bendamustine 
must be completed within this period.  
11.2.4  Dose Specifics  
Induction: Bendamustine will be administered at 90 mg/m²  intravenously  on Day 1 and 
Day 2 of every 28 day cycle for 6 cycles . 
NOTE:  Per investigator discretion, bendamustine may be started at 70 mg/m2 in 
patients over the age of 75 years with comorbid conditions or patients over the age of 80 years without comorbid conditions.  
11.2.5  Preparation  
Refer to commercial package insert or institutional guidelines for preparation of bendamustine.  
11.2.6  Route of Administration  
Bendamustine will be administered as an IV infusion per institutional guidelines  and 
package insert  at a dose of 90 mg/m
2 on days 1 and 2 of each 28- day cycle.  
NOTE:  Per investigator discretion, bendamustine may be started at 70 mg/m2 in 
patients over the age of 75 years with comorbid conditions or patients over the age of 80 years without comorbid conditions.  
If medical conditions necess itate, e.g., fluid management issues or infusion reactions, 
the infusion may be given over a longer period of time. In– line filters are not required 
for administration. Unless there are extenuating circumstances, all of the drug should be administered to the patient with the exception of what remains in the line. Be sure to document any problems you may encounter with the infusion. If for any reason the drug cannot be entirely administered, please measure the remaining volume in the infusion bag and record on your source documentation.  
11.2.7  Dosage in Renal or Hepatic Failure  
In a population pharmacokinetic analysis of bendamustine in patients receiving 120 
mg/m
2 there was no meaningful effect of renal impairment (CrCL 40- 80 mL/min, N=31) 
on the pharmacokinetics of bendamustine. Bendamustine has not been studied in patients with CrCL <40 mL/min. These results are however limited, and therefore bendamustine should be used with caution in patients with mild or moderate renal 
impairment. Bendamustine should not be used in patients with CrCL <40 mL/min.  
In a population pharmacokinetic analysis of bendamustine in patients receiving 120 
mg/m
2 there was no meaningful effect of mild (total bi lirubin ≤ ULN, AST ≥ ULN to 2.5x 
ULN, and/or ALP ≥ ULN to 5.0x ULN, N=26) hepatic impairment on the pharmacokinetics of bendamustine. Bendamustine has not been studied in patients with moderate or severe hepatic impairment. These results are however limited, and 
therefore bendamustine should be used with caution in patients with mild hep atic 
impairment. Bendamustine should not be used in patients wit h AST or ALT ≥ 3.0x ULN 
and total bilirubin ≥ 1.5x  ULN. 
11.2.8  Drug Interactions  
Bendamustine is a substrate for the cytochrome P450(CYP) 1A2 isoenzyme.  
Bendamustine is metabolized to minimally active metabolites by CYP1A2. Concurrent administration of a CYP1A2 inhibitor such as atazanavir, cimetidine, ciprofloxacin, 
fluvoxamine, mexiletine, tacrine, thiabendazole, zileuton, norfloxacin, and/or ethinyl 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
51 estradiol may increase bendamustine concentrations in plasma. Caution should be 
exercised, or alternative treatments considered, when co- administering bendamustine 
with a CYP1A2 inhibitor.  
Bendamustine is metabolized to minimally active metabolites by CYP1A2. Concurrent 
administration of a CYP1A2 inducer  such as barbiturates, carbamazepine, and/or 
rifampin may cause a decrease in bendamustine plasma concentrations and a potential decrease in cytotoxicity. The parent compounds are believed to be primarily 
responsible for the cytotoxicity of this agent. Caution should be exercised, or 
alternative treatments considered, when co- administering bendamustine with a 
CYP1A2 inducer.  
Bendamustine is metabolized to minimally active metabolites by CYP1A2. Smoking 
tobacco has been shown to induce CYP1A2, and may cause a decrease  in 
bendamustine plasma concentrations and a potential decrease in cytotoxicity. The parent compound is believed to be primarily responsible for the cytotoxicity of this agent. Caution should be exercised, or smoking cessation considered, when co-
administering bendamustine with a CYP1A2 inducer.  
11.2.9  Incompatibilities  
No incompatibilities are known (no data is available) . 
11.2.10  Side Effects  
Please refer to Package Insert.  
11.2.11  Nursing/Patient Implications  
1. Monitor CBC, platelet count. Advise patients of increased risk of infection with 
absolute neutrophil count less than 500 cells/mm
3 and increased risk of bleeding 
with platelet counts less than 20,000 cells/mm3. Advise patients to call the clinic if 
they develop a fever above 101oF or notice any easy bruising, petechiae (pinpoint 
red spots on skin), or prolonged bleeding.  
2. Advise patient of possible alopecia, although this is very uncommon with 
bendamustine therapy.  
3. Assess hydration and fluid balance. Patients should be encouraged to have at 
least 1 liter of fluids per day for  72 hours after administration.  
4. Consider premedication with antiemetics.  
5. Observe for possible phlebitis at injection site.  
11.3 Rituximab39,40 
Rituximab will be obtained by the individual study sites as standard of care tre atments from 
commercial stock. Refer to commercial package inserts for full prescribing information.  
Biosimilars for rituximab  are permitted. 
11.3.1  Other Names  
IDEC -C2B8,  Chimeric  anti-CD20  monoclonal  antibody,  Rituxan . 
11.3.2  Classification  
Antibody  
 
 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
52 11.3.3  Storage and Stability 
Rituximab IV:  Store vials  in the refrigerator at  2ºC–8ºC (36ºF –46ºF). Protect  vials from 
direct  sunlight. Once diluted to a concentration of  1 to 4 mg/mL  in polyvinylchloride  or 
polyolefin IV bags  containing normal  saline  or 5% dextrose, the product is  stable for up 
to 24 hours  at 2ºC–8ºC (36ºF –46ºF) , and at room temperature  for an additional  12 
hours  after refrigeration (for a maximum period  of 36 hours) if protected  from light. 
Rituximab SQ:  Store vials  in the  refrigerator at  2ºC–8ºC (36ºF –46ºF) in the original  
carton to protect  from light. Do not freeze.  
Biosimilars  for rituximab are permitted. Refer to package insert for storage and stability 
parameters.  
11.3.4  Dose Specifics  
Induction: Rituxi mab will be administered at 375 mg/m²  intravenously  every  28 days for 
6 cycles . 
NOTE:  For patients that do not have a Grade 3- 4 infusion related adverse event, 
Cycle 2 -6 may be given as a “rapid” IV infusion at 375 mg/m2 per package 
insert.  
Additionally, i f the first two cycles  (or two consecutive cycles)  of rituximab are 
well tolerated, IV rituximab may be replaced with 1400 mg/23,400 units SQ 
rituximab/hyaluronic acid on Day 1 of Cycle  3-6 (or after 2 consecutive cycles 
are well tolerated), per rituximab/hyaluronic acid package insert.  
Maintenance : After 6 cycles of venetoclax, bendamustine and rituximab, subjects 
responding to therapy may receive maintenance rituximab IV or SQ (one dose every 
8 ± 2 weeks for 12 doses or 24 months whichever comes first) per physician and 
patient preference.  
Biosimilar s for rituximab are permitted. Refer to package insert for dose specifics.  
11.3.5  Preparation  
Rituximab IV:  Withdraw  the necessary  amount of rituximab and dilute  to a final 
concentration of 1 to 4 mg/mL  into an infusion  bag containing either  0.9% Sodium  
Chloride or 5% Dextrose  in Water.  Gently  invert  the bag to mix the solution.  Caution  
should be taken  during the preparation of  the drug, as  shaking can cause  aggregation  
and precipitation of the antibody.  
Rituximab preparation may also be done per institutional standards.  
Rituximab SQ:  Subcutaneous  injection  is supplied as  a sterile preservative -free liquid 
solution in a  single -dose  vial. 
Biosimilars  for rituximab are permitted. Refer to package insert for preparation 
instructions.  
11.3. 6 Route of Administration  
Rituximab IV: Rituximab should be given as a “standard” IV infusion at 375 mg/m2 
for Cycle 1 per institution guidelines and package insert. For patients that do not 
have a Grade 3- 4 infusion related adverse event, Cycle 2- 6 may be  given as a “rapid” 
IV infusion at 375 mg/m2 per institution guidelines and package insert. Patients that 
do have a Grade 3- 4 infusion related adverse event should receive the “standard” 
infusion rate for the subsequent cycle. Patients may receive the “rap id” infusion 
schedule if the prior infusion was not associated with a Grade 3- 4 infusion related 
adverse event.  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
53 Rituximab SQ:  1400 mg/23,400 units SQ rituximab/hyaluronic acid on Day 1 of Cycle  
3-6 (or after two consecutive cycles are well tolerated), per rituximab/hyaluronic acid 
package insert . 
Biosimilars  for rituximab are permitted. Refer to package insert for route of 
administration instructions.  
11.3.7  Incompatibilities  
Rituximab IV: Do not mix  or dilute  rituximab with other  drugs. No incompatibilities  
between rituximab and polyvinylchloride  or polyethylene  bags  have  been observed.  
Rituximab Biosimilars:  Refer to package insert for incompatibilities.  
11.3.8  Side Effects  
Please refer to Package Insert.  
11.3.9  Nursing /Patient Implications  
1. Monitor  blood  pressure, pulse,  respiration, and temperature  every  15 minutes  x 
4 or until stable and then hourly  until the infusion  is discontinued or per standard 
of care . 
2. Have  epinephrine for subcutaneous  injections,  diphenhydramine  for intravenous  
injection,  and resuscitation  equipment  for emergency  management of 
anaphylactoid reactions  available.  
3. Monitor  and alter infusion  rates  in the presence of toxicities.  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
54 12. Statistical Considerations 
12.1 Study Design,  Sample Size Considerations  & Statistical Analyses  
12.1.1  Primary Endpoint  
The primary endpoint of this single arm Phase II study is  CR rate after 6 cycles of BR 
+ venetoclax. A 15% improvement in t he historical post -induction CR rate of 70% to 
85% is of interest. A total of 56 patients  will be enrolled, 53 of whom are expected to 
be eligible and treated.  There will be 90% power to detect the 15% improvement in 
CR rate from 70% using one-sided exact binomial test with 10% Type I error . This 
treatment combination will be considered worthy  of further investigation if 42 or more 
eligible and treated patients achieve  CR. The efficacy population consists of all eligible 
and treated patients.  
12.1.1.1  Revised Study Design  
Preliminary data from a similar cohort of patients as that enrolled in this 
study indicates that post -induction CR rate is 60%, not 70% as initially 
assumed. In addition, the observed study accrual rate (1.1 patients/month) 
is significantly lower than the planned/expected study accrual rate of 2.3 
patients/month. For both reasons, the study was redesigned to reflect the current historical CR rate and with a lowered sample size for prompt primary endpoint readout. Accrual before this redesign is 25 patients  as of 
10/11/2021. 
With a revised accrual goal of 33 patients, 32 patients expected to be eligible 
and treated, there is 81.8% power and 11.6% alpha using exact binomi al 
test to detect a 17% difference in CR rate from 60% to 77%. The null 
hypothesis will be rejected, and treatment combination declared positive if 
≥ 23 (71.9%)  CRs are observed among 32 eligible and treated patients.  
12.1.2  Secondary Endpoints  
Secondary endpoints include progression free survival (PFS) and overall survival 
(OS). PFS  is defined as time from r egistration to disease progression or death from 
any cause, whichever occurs first . Patients that are alive and progression free at the 
time of analysis will be censored at the date of last disease assessment. OS is defined 
as time from registration  to death; patients will be censored at the time of last study 
contact. PFS and OS will be estimated using Kaplan -Meier methodology  and 90% 
confidence interval (CI) around estimates will be presented. Appropriate descriptive 
measures will be used to describe clinical and demographic variables.  
12.2 Planned Analyses  
12.2.1 T oxicity Monitoring  Plan  
12.2.1.1  Tumor Lysis Syndrome 
Tumor Lysis Syndrome ( TLS) is an event of interest in this study. TLS risk 
factors are listed in Section 5.3,  TLS monitoring plan is detailed in Section 
5.4 and “Definitions for Tumor Lysis Syndrome” noted in Appendix IV. The 
risk for TLS will be assessed among the first 19 patients  accrued to this 
study who received venetoclax treatment  for at least 3 cycles with no hold 
to accrual . Given the expected clinical TLS rate of 5%, the probability of 
observing at least one clinical TLS among 19 patients is 62%, and 82% 
among 33 patients.  
  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
55 A TLS incidence rate of no more than 15% ( ≤ 3 out of 19 patients) i s 
permissible on this study. If the observed TLS is ≥ 21% (≥ 4 out of 19 
patients) then a detailed review of TLS cases will be conducted by the Data 
Safety Monitoring Board (DSMB). This is the boundary and the DSMB could 
recommend closing the study due to high incidence of TLS. If the true 
incidence of TLS is 30% or higher, there is at least 87% probability of crossing the boundary. Whereas, if the true incidence of TLS is 10% there is only 11% chance of crossing the boundary.  
12.2.1.2  Non- Diseas e Related Death on Treatment  
Deaths during induction have been reported in prior studies with BR and 
novel combinations, particularly bortezomib and lenalidomide.
13,14 The 
combined rate of non- disease related death in these studies is 
approximately 5.5%, which is considered unacceptable. Non- disease 
related death, defined as death from any cause not due to mantle cell 
lymphoma and occurring at any time from Cycle 1, Day 1 to end of 
treatment , will be monitored during the study and each event will be reporte d 
to the DSMB. In addition to reporting each non- disease related death event 
to the DSMB for review, the cumulative observed number of events will be assessed, based on the presented operating characteristics, at specific accrual stages specified in the table below. These accrual stages include 
after 19, 28,  and 33 patients enrollment . If at any of the accrual stages the 
specified boundary for that stage is crossed, the study will pause enrollment and await DSMB review and recommendations. During the review, the DSMB may decide that a death event is not related to treatment and may exclude the event from further calculations (i.e. accident or suicide).  
From the table, at the 19 patient  enrollment and treatment milestone,  the 
expected number of non- disease related death is 1 (based on the 5.5% rate 
reported from referenced studies). If ≥ 2 such death events occur (i.e. boundary is crossed) among 19 patients then the DSMB will review all non-disease related death cases. There is 8.1%, 28.1%, 45.6%, 58.0%, 68.3%, and 80.2% probability of crossing the boundary if the true underlying non-disease related death rate is 2.5%, 5.5%, 8%, 10%, 12%, and 15% 
respectively.  
If at any time there are greater than 5 non- disease related deat hs during 
induction, the study may  close for safety. If the true non- disease related 
death rate is 5.5% then the probability of observing >5 events among 33 
patients is only 0.8%. Whereas the probability of observing >5 events is 
10.6% if the true n on-disease related death rate is 10%, and 67.1% if the 
true underlying death rate is 20%.  
 
    
 
  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
56 Table12-1 : Operating Characteristics of Non -Disease Related Death on Treatment  
 Accrual Stage  
(Number of Expected Eligible and Treated 
Patients  
Total Accrual (N= 33) 19 28 33  
*Expected # of deaths based on 5.5% estimate  1 2 2  
Boundary (defined as expected # of deaths + 1)  2 3 3  
Probability of crossing boundary given true 
death rate of  
     a) 2.5%  
     b) 5.5%  
     c) 8% 
     d) 10%  
     e) 12%  
     f) 15%   
 
8.1%  
28.1%  
45.6%  
58.0%  
68.3%  
80.2%   
 
3.2%  
19.8%  
39.1%  
54.1%  
67.0%  
81.3%   
 
4.9% 
27.2% 
49.8% 65.4% 77.5% 89.1%  
*Rounded to the nearest whole number  
12.2.1.3  Other Toxicity  
Toxicity and adverse events for all enrolled patients will be monitored 
throughout the conduct of the study. Toxicity rates, with 90% exact binomial 
CIs, will be estimated for all enrolled patients who received at least one cycle of treatment, irrespective of eligibility. These rates will be estimated for Grade 3 or higher treatment -related toxicities using CTCAE Version 5.0. If 
all 33 patients are treated, the maximum width of a 90% exact CI on the rate 
of Grade 3 or higher treatment -related toxicities will be no wider than 31%. 
The probability of observing at least one rare toxicity event (given a true rate of 5%) is 81.6%. The DSMB will review safety data and may halt the study 
for safety if any grade 4 or higher specific toxicity occurs with an incidence rate of >30% . 
12.2.1.4  Study and Safety Monitoring Plan  
This study will be monitored by the PrECOG DSMB. The D SMB meets twice 
each year , or as frequently as deemed necessary by the DSMB. For each 
meeting, all monitored studies are reviewed for toxicity  and progress toward 
completion. If a safety concern is identified, the DSMB  may recommend 
halting or permanently stopping the trial at any time.  
12.2.2 Analyses of Correlative Studies  
Minimum Residual Disease (MRD)  will be analyzed as a binary endpoint an d 90% 
exact CI  around the estimated MRD negative rate will be reported. This estimate will 
also be reported within levels of response to BR + venetoclax treatment.  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
57 13. Laboratory and Pathology  Correlative Studies 
13.1 Correlative Studies: Mandatory  Tumor Sampl es (if sufficient tissue available)  
13.1.1  Research Tumor Sample Collection  
Pre-treatment, diagnostic pathology specimens  (organ or lymph node biopsy or 
excision)  obtained in the course of standard biopsy or surgery  (if sufficient tissue is 
available, submission is mandatory) . 
Formalin -fixed paraffin- embedded ( FFPE ) blocks  and 5 FFPE tissue on unstained ( 5 
um) slides or if blocks are not available,  up to 15 FFPE tissue  on unstained (5 um) 
slides plus H&E slide (if tissue is limited, then minimum of 10 s lides).  
NOTE : If additional tissue from initial biopsy is not available, repeat biopsy will not be 
required (no biopsy should be performed solely for the purposes of obtaining research 
samples) . 
Five slides per patient will be sent to Adaptive Biot echnologies for baseline calibration 
(obtained from a patient at the time of diagnosis and before treatment has begun) 
measurement for  MRD . 
If block s and/or slides are unavailable and bone marrow is involved with mantle cell 
lymphoma, obtain two 2 mL EDTA tubes of  bone marrow aspirate (one for baseline 
MRD analysis and one for future research). If blocks/slides and bone marrow are unavailable and peripheral blood is involved with mantle cell lymphoma obtain one 4 
mL and one 6 mL EDTA tubes of peripheral blood (one for baseline MRD analysis and 
one for future research).
 If baseline samples (blocks/slides, bone marrow, and/or 
peripheral blood) are not submitted at baseline for MRD  (i.e., not involved with mantle 
cell lymphoma) , then patients will be allowed to remain on study but MRD samples will 
not be collected during the study.  
Optional: Any tumor biopsy samples  obtained during treatment or post -treatment  
(FFPE  blocks or up to 15 FFPE tissue on unstained (5 um) slides plus H&E 
slide) will be requested for research if conducted due to concerns for 
progressive disease and banked for future research.  
Block s or remaining slide sampl es will be sent to the ECOG -ACRIN Central 
Biorepository Pathology Facility (CBPF)  for storage.  
13.1.2 Pathology Sample Processing and Shipment  
All samples collected will be labeled with a unique numeric identifier that will be coded for patient privacy protection.  
Kits will be supplied. Instructions and shipping address will be provided. Refer to the PrE0405  Lab Manual for details.  
13.1.2.1  MRD Pathology Samples to Adaptive Biot echnologies  
Sites should submit 5 FFPE slides (minimum of 3 slides) from a tumor tissue block. Thickness of the sections should be at 5 micron.  
Samples should be shipped Monday -Thursday . Samples will be shipped 
ambient via overnight courier approximately every 6 months on a set schedule. For all patients the initial shipment should  include Baseline  (tissue 
sample)  and End of Treatment  (bone marrow, if collected and peripheral 
blood)  samples.  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
58 13.1.2.2  Remaining Pathology Samples to Central Lab  
Sites should submit FFPE diagnosis  tumor tissue blocks or up to 10 FFPE 
slides  plus H&E slide from a tumor tissue block within 6 months of patient 
registration. Thickness  of the sections should be at 5 micron.  
Sites should submit any optional tumor  samples  obtained during treatment 
or post -treatment  (formalin -fixed paraffin-e mbedded (FFPE) blocks or up to 
15 FFPE tissue (5 microns) on unstained slides plus H&E slide)  within 3 
months of procedure.  
A copy of the pathology report from initial diagnosis and/or subsequent 
tumor sampling should be sent when the sample is shipped. Samples 
should be shipped Monday -Thursday . Samples will be shipped ambient 
via overnight courier  to the CBPF  approx imately every 6 months.  
13.2 Correlative Studies: Mandatory Bone Marrow  Samples  
All samples collected will be labeled with a unique numeric identifier that will be coded for 
patient privacy protection.  
Kits will be supplied. Instructions and shipping address will be provided. Refer to the PrE0405 Lab Manual for details.  
13.2.1  Research Bone Marrow Sample Collection  
• Screening (only if FFPE tumor samples are not available  and bone marrow 
involved with mantle cell lymphoma ) 
- One 2 mL EDTA tube for MRD calibration sample 
- One 2 mL EDTA  tube for future research  
• End of Treatment (submission is mandatory if collected) 
- One 2 mL EDTA  tube for MRD analysis  
Please note,  if bone marrow is positive for mantle cell lymphoma at baseline, an end 
of treatment bone marrow must  be collected to confirm response. 
13.2.2  Research Bone Marrow Processing and Shipment  
13.2.2.1  MRD Bone Marrow  Aspirate Samples to Adaptive Biot echnologies  
Store  2 mL EDTA tube in the freezer at ≤ -80°C or colder until  shipped to 
Adaptive Biot echnologies . 
Samples should be shipped Monday -Thursday . Samples must be shipped 
on dry ice via overnight courier approximately every 6 months on a set 
schedule. For all patients the initial shipment should  include Baseline (tissue 
sample) and End of Treatm ent (bone marrow  aspirate, if collected  and 
peripheral blood) samples.  
13.2.2.2  Remaining Bone Marrow Aspirate Samples to Central Lab, if applicable  
Store  2 mL EDTA tube in the freezer at ≤ -80°C or colder until  shipped to 
ECOG -ACRIN CBPF . 
Bone marrow aspi rate samples should be submitted approximately every 6 
months , as applicable. A copy of the BM report should be sent when the 
sample is shipped. Samples should be shipped Monday -Thursday . 
Samples must be shipped on dry ice via overnight courier  to the CBPF . 
 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
59 13.3 Correlative Studies: Mandatory  and Optional  Peripheral Blood Samples  
All samples collected will be labeled with a unique numeric identifier that will be coded for 
patient privacy protection.  
Kits will be supplied. Instructions and shipping address will be provided. Refer to the PrE0405 
Lab Manual for details.  
MRD Samples are mandatory. Samples for future research are optional  except screening 
sample is mandatory, as applicable. 
13.3.1  Research Blood Sample Collection  
• Screening  (only if FFPE tumor and BM sa mples are not available and 
peripheral blood involved with mantle cell lymphoma ) 
- One 4 mL EDTA tube  for MRD calibration sample 
- One 6 mL EDTA tube for future research  
• Cycle 1, Day 1  
- One 10 mL red top tube for future research  
- One 6 mL EDTA  tube for future research  
• Cycle 2 , Day 1  (If sample drawn and cycle delayed, this sample may be used,  
do not need to repeat)  
- One 10 mL red top tube for future research  
- One 6 mL EDTA  tube for future research  
• Cycle 4, Day 1  (If sample drawn and cycle delayed,  this sample may be used, 
do not need to repeat) 
- One 10 mL red top tube for future research  
- One 6 mL EDTA  tube for future research  
• End of Treatment 
- One 4 mL EDTA tube for MRD analysis  
- One 10 mL red top tube for future research  
- One 6 mL EDTA  tube for future research  
• At Time of Progression  
- One 4 mL EDTA tube for future research  
- One 10 mL red top tube for future research  
- One 6 mL EDTA  tube for future research  
13.3.2  Research Blood Sample Processing and Shipment 
13.3.2.1  MRD Peripheral Blood Samples to Adaptive Biot echnologies  
Store  4 mL EDTA tube in the freezer at ≤ -80°C or colder until  shipped to 
Adaptive Biotechnologies . 
Samples should be shipped Monday -Thursday . Baseline and End of 
Treatment samples must be shipped on dry ice via overnight courier 
approximately every 6 months on a set schedule. For all patients the initial shipment should include Baseline (tissue sample) and End of Treatment 
(bone marrow aspirate, if collected and peripheral blood) samples.  
NOTE:   4 mL EDTA tube sample collected at time of progression for future 
research will be stored at site. PrECOG will instr uct sites when to 
ship these samples  to the CBPF (approximately every 6 months) . 
 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
60 13.3.2.2  Remaining Peripheral Blood Samples to Central Lab  
Red Top Tube  (10 mL)  Processing for Serum  
Gently mix the blood sample by inversion 5 times (do not shake). Allow the 
sample to sit at room temperature for 30- 60 minutes in vertical positon until 
a clot has formed. If the blood is not centrifuged immediately after the 
clotting time (30- 60 minutes at room temperature), the tubes should be 
refrigerated (4°C) for no longer than 4 hours.  
Once the clot has formed, the sample is ready for centrifugation. Centrifuge for 15 minutes at room temperature at 1200 RPM  or per institutional 
practices . Immediately aliquot and store the resulting serum into two (2) 
properly labeled polypropylene tubes. Be careful to not disturb the clot. Store the samples in the freezer at -80°C until they are shipped to the  CBPF . 
EDTA Tube  (6 mL) Processing for Plasma and Buffy Coat  
**Samples should be processed within 4 hours, but at limit of 
processing being same day ** 
• Gently mix blood sample by inversion 10 times (do not shake).  
• Place tube immediately on wet ice for 5 minutes.  
• Centrifuge at 1200 RPM for 15 minutes at 4° C. If a refrigerated 
centrifuge is not available, spin sample at room temperature (1200 RPM for 15 minutes)  or per institutional practices . Immediately place the tube 
on wet ice after centrifugation.  
After centrifugation, the plasma layer will be at the top half of the tube. The 
nucleated cells (WBC) will be in a whitish layer, called the “buffy coat”, just 
under the plasma and above the red blood cells.  
Plasma  Preparation:  
• Using a transfer pipette take the top two- thirds of the plasma and 
transfer plasma into a 15 mL conical centrifuge tube, be careful not to 
disturb the buffy coat layer in the EDTA tube ( NOTE:  see below for buffy 
coat processing instructions). Centrifuge the 15 mL conical tube at 1200 
RPM for 15 minutes at 4° C. If a refrigerated centrifuge is not available, 
spin sample at room temperature (1200 RPM for 15 minutes). Immediately place the conical tube on wet ice after centrifugation.  
• Transfer equal amounts of plasma into two (2) properly labeled 
polypropylene tubes for cryopreservation being careful not to disturb the 
small PBMC/pellet . 
• Store the two aliquots of plasma samples in the freezer at ≤ -80°C or 
colder until they are shipped to the CBPF . 
Buffy Coat Preparation: 
• From the EDTA tube remove and aliquot the “buffy coat”; be careful not 
to disturb the layer of  red blood cells.  
• Store the  aliquot of cells in one (1)  properly labeled polypropylene tube 
for cryopreservation.  
• Store the sample in the freezer at  ≤ -80°C or colder until it is sh ipped to 
the CBPF . 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
61 Plasma and buffy coat samples should be batched together and shipped 
approximately every 6 months. Individual patients should only be included in the shipment if all of their  samples have been completed  through the End 
of Treatment sample. Samples should be shipped Monday -Thursday . 
Samples must be shipped on dry ice via overnight courier  to the CBPF . 
13.4 Assay Methodology  
13.4.1  MRD Analysis  
Adaptive’s NG S MRD As say is a process for measuring minimal residual d isease 
(MRD) and will be used to analyze calibration samples and end of treatment  samples  
from patients . Exploratory analyses of B -cell r eceptor repertoire loci will be performed 
to (i) determine disease- correlated clonotypes  from each of the c alibration s amples 
and (ii) assess the levels of Index Clonotypes (and therefore levels of MRD) in end of 
treatment  samples.  
13.4.2  Planned Analysis for Future Research Samples  
Analysis  may be performed depending on resources, sample qual ity and availability 
for possible future molecular and genomic  testing. 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
62 14. Administrative  
14.1 Protocol Compliance  
The study shall be conducted as described in this protocol. All revisions to the protocol must 
be discussed with, and be prepared by PrECOG and/or representatives. The Investigator should not implement any deviation or change to the protocol or consent without prior review and documented approval from PrECOG and/or representatives and the Institutional Review 
Board ( IRB) of an amendment, except where necessary to eliminate an immediate hazard(s) 
to study patients.  
If a deviation or change to the approved protocol is implemented to eliminate an immediate hazard(s) prior to obtaining IRB approval, notification will be submitted to the IRB for review and approval as soon as possible afterward. Documentation of approval signed by the chairperson or designee of the IRB(s) should be in the study records. If PrECOG and/or representatives provides an amendment that substantially alters the study design or i ncreases 
the potential risk to the patient; the consent form must be revised and submitted to the IRB(s) for review and approval; the revised form must be used to obtain consent from patients currently enrolled in the study if they are affected by the Amendment; and the new form must be used to obtain consent from new patients prior to study entry. Information as to who investigators should send correspondence will be provided in additional study documents.  
14.2 Institutional Review Board 
Before study initiation, the Investigator must have written and dated approval from their respective IRB for the protocol, consent form, patient recruitment materials/process and any other written information to be provided to patients. The Investigator should also provide the IRB with a copy of the Investigator Brochure or product labeling, and any updates.  
The Investigator should provide the IRB with reports, updates, and other information (e.g., 
Safety Updates, amendments, and administrative letters) according to regulatory 
requirements, IRB or study site procedures.  
14.3 Informed Consent Procedures  
Investigators must ensure that patients who volunteer for clinical trials or their legally acceptable representative are clearly and fully informed about the purpose, potential risks and other information.  
A protocol specific informed consent form (ICF) template will be provided to sites. Preparation of the site- specific consent form is the responsibility of the site Investigator and must include 
all applicable regulatory and IRB requirements, and must adhere to Good Clinical Practices (GCP) and to the ethical principles that have their origin in the Declaration of Helsinki. All changes to the ICF template will be approved by PrECOG and/or their representatives prior to implementation.  
In accordance with the Health Information Portability and Accountability Act (HIPAA), the consent process will also include written authorization by patients to release medical information to allow PrECOG and/or its agents, regulatory authorities, and the IRB of record at the study site for access to patient records and medical information relevant to the study, including the medical history. This will be documented in the informed consent form or other approved form obtained at the time of informed consent per institutional policies. This form 
should also be submitted to PrECOG and/or its agents for review prior to its implementation.  
The Investigator must provide the patient or legally acceptable representative with a copy of 
the consent form and written information about the study in the language in which the patient is most proficient. The language must be non- technical and easily understood. The Investigator 
should allow time necessary for patient or patient's legally acceptable representativ e to inquire 
about the details of the study, then informed consent must be signed and personally dated by 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
63 the patient or the patient's legally acceptable representative and by the person who conducted 
the informed consent discussion. The patient or legally  acceptable representative should 
receive a copy of the signed informed consent and any other written information provided to study patients prior to patient's participation in the trial. The investigator is responsible for 
assuring adequate documentation of this process and for storage and maintenance of the 
original signed consent  form for each patient/subject.  
The informed consent and any other information provided to patients or the patient's legally acceptable representative, should be revised whenever  important new information becomes 
available that is relevant to the patient's consent, and should receive IRB approval prior to use. The Investigator, or a person designated by the Investigator should inform the patient or the 
patient's legally acceptable  representative of all pertinent aspects of the study and of any new 
information relevant to the patient's willingness to continue participation in the study. This 
communication should be documented in the patient record. During a patient's participation i n 
the trial, any updates to the consent form and any updates to the written information will be provided to the patient.  
14.4 Safety Communication  
Investigators will be notified of all AEs that are serious, unexpected, and definitely, probably, or possibly  related to the investigational product. Upon receiving such notices, the Investigator 
must review and retain the notice with the Investigator Brochure and submit a copy of this information to the IRB according to local regulations. The Investigator and IRB will determine 
if the informed consent requires revision. The Investigator should also comply with the IRB 
procedures for reporting any other safety information. All revisions should be submitted to 
PrECOG and/or agents for review.  
14.5 Monitoring 
Repres entatives and agents of PrECOG and, as applicable to the study, the manufacturer of 
investigational product must be allowed to visit all study site locations periodically to assess the data, quality and study integrity. The purpose of this visit is to review study records and 
directly compare them with source documents and discuss the conduct of the study with the 
Investigator, and verify that the facilities remain acceptable. Monitoring of drug accountability will also occur.  
The study may be evaluated by other auditors and government inspectors who must be allowed access to electronic Case Report Forms ( eCRFs ), source documents and other study 
files. The Investigator must notify PrECOG of any scheduled visits by regulatory authorities, and submit copies of  all reports. Information as to who investigators should notify of an audit 
or where to address questions will be provided in additional study materials.  
14.6 Study Records  
An Investigator is required to maintain adequate regulatory files with corresponding communication and approvals, accurate histories, observations and other data on each 
individual treated. Full details of required regulatory documents will be provided in additional 
study materials. Data reported on the eCRFs  must be consistent with the source documents  
as part of the patient record.  
The confidentiality of records that could identify patients must be protected, respecting the privacy and confidentiality rules in accordance with the applicable regulatory requirement(s).  
A study specific si gnature record will be maintained to document signatures and initials of all 
persons at a study site who are authorized to make entries and/or corrections on eCRFs as well as document other study -specific roles.  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
64 14.7 Electronic Case Report Form (eCRF) Information  
Additional information regarding eCRF instructions, timelines for data entry/ submission and 
query completion can be found in supplemental materials provided to the site. Sites will be expected to complete eCRFs as per the schedule provided and submit all relevant data as per 
the specified timelines. All items recorded on eCRFs must be found in source documents.  
The completed eCRF must be promptly reviewed, electronically signed, and dated by the 
Principal Investigator.  
Instructions for management of patients who do not receive any protocol therapy:  
If a patient is registered and does not receive any assigned protocol treatment, baseline, Serious Adverse Event and follow -up data will still be entered and must be submitted according 
to the eCRF instructions. Document the reason for not starting protocol treatment on the appropriate electronic off treatment form.  
14.8 Records Retention  
FDA Regulations (21CFR 312.62) require clinical investigators to retain all trial -related 
documentation, including sour ce documents for the periods described below for studies 
performed under a US Investigational New Drug ( IND): 
• two years after the FDA approves the marketing application, or  
• two years after the FDA disapproves the application for the indication being studied, or  
• two years after the FDA is notified by the sponsor of the discontinuation of trials and that an 
application will not be submitted.  
The Investigator must retain investigational product disposition records, copies of eCRFs (or electronic files), and source documents for the maximum period required by applicable 
regulations and guidelines, or Institution procedures, whichever is longer. The Investigator must contact PrECOG and/or representatives prior to destroying any records associated with the s tudy.  
Information as to who investigators should contact for questions will be provided in additional 
study documents. PrECOG and/or representatives will notify the Investigator when the trial records for this study are no longer needed.  
 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
65 15. References  
1. Al-Hamadani M, Haber mann TM, Cerhan JR , et al. Non- Hodgkin lymphoma subtype distribution, 
geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer 
Data Base from 1998 to 2011. Am J Hematol.  2015 Sep;  90(9):790- 5. 
2. Cohen JB,  Han X , Jemal A , et al. Deferred therapy is associated with improved overall survival in 
patients with newly diagnosed mantle cell lymphoma. Cancer.  2016 Aug 1;  122(15):2356- 63. 
3. Rummel M, Niederle N , Maschmeyer G , et al. Bendamustine plus rituximab versus CHOP plus 
rituximab as first -line treatment for patients with indolent and mantle- cell lymphomas: an open-
label, multicentre, randomised, phase 3 non- inferiority trial. Lancet.  2013 Apr 6;  381(9873):1203-
10. 
4. Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine- rituximab or R -
CHOP/R- CVP in first -line treatment of indolent  NHL or MCL; the BRIGHT study. Blood . 2014; 
123(19): 2944- 2952.  
5. Rummel M, Kaiser U , Balser C , et al. Bendamustine plus rituximab versus fludarabine plus 
rituximab for patients with relapsed indolent and mantle- cell lymphomas: a multicentre, 
randomised, open- label, non- inferiority phase 3 trial. Lancet Oncol.  2016 Jan;  17(1):57- 66. 
6. Gyan E , Sonet A , Brice P , et al. Bendamustine and rituximab in elderly patients with low -tumour 
burden follicular lymphoma. Results of the LYSA phase II BRIEF st udy. Br J Haematol.  2018 Oct;  
183(1):76- 86. 
7. Laurenti L, Innocent  I, Autore  F et al, Bendamustine in combination with rituximab for elderly 
patients with previously untreated B- cell chronic lymphocytic leukemia: A retrospective analysis of 
real-life practice in Italian hematology departments . Leuk Res . 2015 Oct; 39(10): 1066- 70. 
8. Salles G, Seymour JF , Offner F , et al. Rituximab maintenance for 2 years in patients with high 
tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 
3, randomised controlled trial. Lancet.  2011 Jan 1;  377(9759):42- 51. 
9. Rummel M, Knauf W, Goerner M, et al. Two years rituximab maintenance vs. observation after 
first-line treatment with bendamustine plus rituximab (B -R) in patients with mantle cell lymphoma: 
First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7 -2008 MAINTAIN trial).  Presented June 5, 2016.  
https://meetinglibrary.asco.org/ 
record/123330/abstract . 
10. Vidal L , Gafter -Gvili A, Dreyling  M, et al. Rituximab Maintenance (RM) for Patients with Mantle Cell 
Lymphoma (MCL): A Systemic Review and Meta- Analysis of Randomized Controlled Trials. Blood  
2014  124:4466. http://www.bloodjournal.org/content/124/21/4466 . 
11. Rituximab, Bendamustine Hydrochloride, and Bortezomib followed by Rituximab and Lenalidomide 
in Treating Older Patients with Previously Untreated Mantle Cell Lymphoma, clinicaltrials.gov Identifier NCT0145752. 
12. A study of the bruton’s tyrosine kinase inhibitor ibrutinib given in combination with bendamustine 
and rituximab in patients with newly diagnosed mantle cell lymphoma, clinicaltriasl.gov identifier [STUDY_ID_REMOVED].  
13. Albertsson- Lindbald A, Kolstad A, Laurell A, et al. Lenalidomide- bendamustine- rituximab in 
patients older than 65 years with untreated mantle cell lymphoma. Blood. 2016; 128(14): 1814-
1820.  
14. Gressin R , Daguindau N , Tempescul A , et al. A phase 2 study of rituximab, bendamustine, 
bortezomib and dexamethasone for first -line treatment of older patients with mantle cell lymphoma. 
Haematologica.  2019 Jan; 104(1):138- 146. 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
66 15. Grigg A , Dyer  M, González  Díaz M, et al.  Safety and effi cacy of obinutuzumab with CHOP or 
bendamustine i n previously untreated follicular l ymphoma. Haematologica. 2017 102:765- 772, 
DOI: 10.3324/haematol.2016.152272. 
16. Sehn LH, Chua N, Mayer J,  et al. Obinutuzumab plus bendamustine versus bendamustine 
monotherapy in patients with rituximab- refractory indolent non- hodgkin lymphoma (GADOLIN): a 
randomized, controlled, open- label, multicenter, phase 3 trial. Lancet Oncol . 2016 17(8):1081-
1093, DOI : 10.1016/S1470- 2045(16)30097-3. 
17. Hiddemann W, Barbui AM, Canales MA, et al. Immunochemotherapy with obinutuzumab or 
rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of 
chemotherapy on efficacy and safety. J Clin Oncol.  2018 36(23):2395- 2404. DOI 
10.1200/JCO.2017.76.8960. PMID 29856692. 
18. Visco, C,  Chiappella A, Nassi L, et al. Rituximab, bendamustine, and low -dose cytarabine as 
induction therapy in elderly patients with mantle cell lymphoma: a multicenter, phase 2 trial  from 
Fondazione Italiana Linfomi.  Lancet Haematol . 2017; 4(1); epub e15- 23. 
19. Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic 
lymphocytic leukemia.  N Engl J Med. 2016; 374(4): 31 1-22. 
20. Davids MS, Roberts AW, Seymour JF, et al. Phase I first -in-human study of venetoclax in patients 
with relapsed or r efractory non- Hodgkin lymphoma.  J Clin Oncol. 2017, Mar 10; 35(8):826- 833. 
21. Abbvie. Venetoclax/ABT -199 Investigator's Brochure, Version 8; Date: 15 February 2017.  
22. VENCLEXTA™ (venetoclax) tablets, for oral use;  Initial U.S. Approval: 2016 ; Highlights of 
Prescribing Information; Revised 12/2017.  
23. Anderson NM, Harrold I, Mansour MR, et al. BCL2- specific inhibitor ABT -199 synergizes strongly 
with cytarabine against the early immature LOUCY cell line but not more- differentiated T -ALL cell 
lines. Leukemia. 2014; 28(5): 1145- 1148. 
24. Boegenberger JM, Kornblau SM, Pierceall WE, et al. BCL- 2 family proteins as 5- Azacytidine -
sensitizing targets and determinants of response in myeloid malignancies. Leukemia. 2014; 28(8): 1657- 1665.  
25. Johnson- Farley N, Veliz J, Bhagavathi S, and Bertino JR.  ABT-199, a BH3 mimetic that specifically 
targets BCL- 2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in “double 
hit” lymphoma cells.  Leuk Lymphoma. 2015; 56(7):  2146- 2152. 
26. Zinzani PL, Topp, MS, Yuen SLS, et al. Phase 2 study of Venetoclax plus  rituximab or randomized 
ven plus bendamustine+rituximab (BR) versus BR in patients with relapsed/refractory follicular lymphoma:  interim data [abstract]. Blood.  2016; 128(22): Abstract 617.  
27. Ladetto M, Bruggemann M, Monitillo L, et al.  Next -generation sequencing and real -time 
quantitative PCR for minimal residual disease detection in B -cell disorders.  Leukemia. 2014; 28: 
1299- 1307.  
28. Hoster E, and Pott, C. Minimal residual disease in mantle cell lymphoma: insights into biolog y and 
impact on treatment. Hematology Am Soc Hematol Educ Program. 2016; 1: 437- 445. 
29. Pott C, Macintyre E, Delfau- Larue MH, et al.  MRD eradiation should be the therapeutic goal in 
mantle cell lymphoma and may enable tailored treatment approaches: results of the intergroup trials of the European MCL Network [abstract] Blood. 2014; 124(21): Abstract 147. 
30. Swerdlow  SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization 
classification of lymphoid neoplasms. Blood 2016;  127:2375- 2390.  
31. Howard SC, Jones, DP and Pui CH. The Tumor Lysis Syndrome. N Engl J Med 2011;  364: 1844-
54. 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
67 32. Cheson BD, Fisher RI, Barrington SF, Cavalli F, et al. Recommendations for Initial Evaluation, 
Staging and Response Assessment of Hodgkin and Non- Hodgkin Lymphoma: the Lugano 
Classification. J Clin Oncol.  2014 Sep 20; 32(27): 3059- 3068.  
33. Barrington SF , Mikhaeel NG , Kostakoglu L , et al. Role of imaging in the staging and response 
assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas 
Imaging Working Group. J Clin Oncol.  2014 Sep 20; 32(27):3048- 58. 
34. Calculate by QxMD; MIPI: Mantle Cell Lymphoma Prognosis; 2020 QxMD Software, Inc.;  
https://qxmd.com/calculate/calculator_149/mipi- mantle -cell-lymphoma- prognosis ; last accessed 
1/27/2020.  
35. MD+Calculate; Mantle Cell Lymphoma International Prognostic Index (MIPI); MDCalc 2005- 2020; 
https://www.mdcalc.com/mantle- cell-lymp homa- international -prognostic -index -mipi; last accessed 
1/27/2020.  
36. Hoster E, Dreyling M, Klapper W et al. A new prognostic index (MIPI) for patients with advanced 
stage mantle cell lymphoma. Blood. 2007; 111:558- 565. 
37. American Society of Hematology , 2008. Correction to Hoster, et al. 111 (7): 558.  Erratum in Hoster 
et al. A new prognostic index (MIPI) for patients with advanced stage mantle cell lymphoma. Blood. 2008; 111: 558- 565. 
38. Treanda 
® (bendamustine hydrochloride) for injection, for intravenous use; Initial U.S. Approval: 
2008;  Highlights of Prescribing Information; Revised 12/2017.  
39. Rituxan® (rituximab) injection,  for intravenous  use; Initial  U.S. Approval:  1997; Highlights of 
Prescribing Information; Revised 4/2016.  
40. Rituxan Hycela™ (rituximab  and hyaluronidase human)  injection,  for subcutaneous use; Initial  U.S. 
Approval: 2017; Highlights of Prescribing Information; Revised 6/2017. 
 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
68 Appendix I : ECOG Performance Status  
 
PS 0  Fully active, able to carry on all pre- disease performance without 
restriction  
PS 1  Restricted in physically strenuous activity but ambulatory and 
able to carry out work of a light or sedentary nature e.g. light 
house work, office work.  
PS 2  Ambulatory and capable of all self -care but unable to carry out 
any work activities. Up and about more than 50% of waking 
hours.  
PS 3  Capable of only limited self -care, confined to bed or chair more 
than 50% of waking hours.  
PS 4  Completely disabled. Cannot carry on any self -care. Totally 
confined to bed or chair.  
Source: Eastern Cooperative Oncology Group, Robert Comis M.D., Group Chair  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
69 Appendix II: Calculation of Creatinine Clearance Using the Cockcroft -Gault Formula  
 
 
(140 - age [years]) (body wt [kg])  
Creatinine clearance for males =  ————————————————— 
(72) (serum creatinine [mg/dL])  
 
 
(140 - age [years]) (body wt [kg])  
Creatinine clearance for females =  ————————————————— x 0.85  
(72) (serum creatinine [mg/dL])  
 
NOTE:  Actual body weight in kg.  
 Source: Gault MH, Longerich LL, Harnett JD, et  al. Predicting glomerular function from adjusted serum 
creatinine (editorial). Nephron 1992; 62:249  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
70 Appendix III:  Additional Excluded and Cautionary Medications 
The following is NOT a complete list of medications that are potentially incompatible with treatment on this 
protocol. As the list of these agents are constantly changing, it is important to regularly consult a frequently updated medical reference. Please refer to the following website for more informat ion: 
http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm  
Clinically Relevant Drug Interactions: Inhibitors and Inducers of Isoenzyme CYP3A  and P- gp 
Inhibitors  
Continuous use of strong and moderate  CYP3A inhibitors , CYP3A inducers  or P-gp Inhibitors  is not allowed. 
If a subject requires continuous use of these drugs they will  be excluded. Consider alte rnative medications . 
NOTE:  In cycles 2- 6 when venetoclax  will not be administered (i.e., Days 11- 28), avoid the use of strong or 
moderate CYP3A inhibitors or P- gp inhibitors 2 to 3 days prior to the next cycle of venetoclax treatment. Also 
avoid the use of strong or moderate CYP3A inducers at least 7 days prior  to the next cycle of venetoclax 
treatment.  
Co-administration with the use of weak CYP3A inducers  and inhibitors is allowed. P-gp substrate should be 
avoided. If a concomitant use is unavoidable, separate dosing of the P -gp substrate at least 6 hours befor e 
venetoclax.  
CYP3A  INHIBITORS  
STRONG INHIBITORS  
boceprevir, clarithromycin, cobicistat, conivaptan, grapefruit juice, idelalisib, indinavir, itraconazole, lopinavir, 
ketoconazole, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, teleprevir, telithromycin, 
troleandamycin, voriconazole  
MODERATE INHIBITORS  
amprenavir, aprepitant, atazanavir, cimetidine, ciprofloxacin, clotrimazole, crizotinib, darunovir, diltiazem, dronedarone, 
erythromycin, fluconazole, fosamprenavir, imatinib, isavuconazole, nifedipine, seville oranges, star fruit, tofisopam, 
verapamil  
CYP3A  INDUCERS  
STRONG INDUCERS  
avasimibe, carbamazepine, enzalutamine, mitotane, phenobarbital, phenytoin, rifampin, St. John’s Wort  
MODERATE INDUCER S 
bosentan, efavirenz, etravirine, modafinil, nafcillin, oxcarbazepine  
P-gp INHIBITORS  (STRONG & MODERATE)  
STRONG  & MODERATE  INHIBITORS  
amiodarone, azithromycin, captopril, carvedilol, cyclosporine, dronedarone, elacridar, felodipine, ginkgo (ginkgo biloba), 
mibefradil, milk thistle (silybum marianum), nitrendipine, quercetin, quinidine, rano lzine, schisandra chinensis, 
telmisartan, ticagrelor, tipranavir, valspodar  
 
 
 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
71 Cautionary Use 
CYP3A  INHIBITORS  
WEAK INHIBITORS  
alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, 
fluvoxamine, ginkgo, goldenseed, isoniazid, nilotinib, oral contraceptives, pazopanib, ranitidine, ranolazine, ticagrelor, 
tipranavir, zileuton  
CYP3A  INDUCERS  
WEAK INDUCERS  
armodafinil, clobazamechinacea, pioglitazone, prednisone,  rufinamide, vemurafenib  
P-gp 
P-gp SUBSTRATES  
aliskiren, ambrisentan, colchicines, dabigatran etexilate, digoxin, everolimus, fexofenadine, indinavir, lapatinib, 
loperamide, maraviroc, nilotinib, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan  
 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
72 Appendix IV : Definitions for Tumor Lysis Syndrome31 
 
Definitions of Tumor Lysis Syndrome  
Metabolic Abnormality  Criteria for Classification of 
Laboratory Tumor Lysis Syndrome * Criteria for Classification of Clinical Tumor 
Lysis Syndrome * 
Hyperuricemia  Uric acid >8.0 mg/ dl (475.8 μmol/liter) 
in adults.   
Hyperphosphatemia  Phosphorus >4.5 mg/dl (1.5 mmol/  liter) 
in adults .  
Hyperkalemia   Cardiac dysrhythmia or sudden death probably 
or definitely caused by hyperkalemia. 
Hypocalcemia  Corrected calcium <7.0 mg/dl (1.75 
mmol/liter) or ionized calcium <1.12 
(0.3 mmol/liter)†  Cardiac dysrhythmia, sudden death, seizure, 
neuromuscular irritability (tetany, paresthesias, 
muscle twitching, carpo pedal spasm, 
Trousseau’s sign, Chvostek’s sign, 
laryngospasm, or bronchospasm), hypotension, 
or heart failure probably or definitely caused by 
hypocalcemia . 
Acute Kidney I njury‡  N/A Increase in the serum creatinine level of 0.3 
mg/dl (26.5 μmol/liter) (or a single value >1.5x  
the upper limit of the age appropriate normal 
range if no baseline creatinine measurement is 
available) or the presence of oliguria, defined as an average urine output of <0.5 mL/kg/hr for 6 hr . 
* In laboratory tumor lysis syndrome, two or more metabolic abnormalities must be present during the same 24-hour 
period within 3 days before the start of therapy or up to 7 days afterward (Grade 3) . Clinical tumor lysis syndrome 
requires the presence of laboratory tumor lysis syndrome plus an  increased creatinine level, seizures, cardiac 
dysrhythmia, or death (Grade 4 or Grade 5[death]) . 
† The corrected calcium level in milligrams per deciliter = measured calcium level in milligrams per deciliter + 0.8 × 
(4 – albumin in grams per deciliter). 
‡ Acute kidney injury is defined as an increase in the creatinine level of at least 0.3 mg per deciliter (26.5 μmol per liter) or a period of oliguria lasting 6 hours or more. By definition, if acute kidney injury is present, the patient has 
clinical tumor lysis syndrome if no other cause can be found . 
Source: Howard SC, Jones, DP and Pui CH. The Tumor Lysis Syndrome. N Engl J Med 2011; 364: 1844- 54. 
Copyright © 2011 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical 
Society.  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
73 Appendix V:  Revised Criteria for Response Assessment32 
Response and 
Site PET-CT–Based Response  CT-Based Response  
Complete  Complete Metabolic R esponse  Complete Radiologic Response  
(all of the following)  
 Score 1, 2, or 3*- with or without a residual mass on 
5PS† Target nodes/nodal masses must regress 
to ≤ 1.5 cm in LDi  
Lymph Nodes and 
Extralymphatic S ites It is recognized that in Waldeyer's ring or extranodal  
sites with high physiologic uptake or with activation 
within spleen or marrow (e.g. , with chemotherapy or 
myeloid colony -stimulating factors), uptake may be 
greater than normal mediastinum and/or liver. In this 
circumstance, complete metabolic response may be 
inferred if uptake at sites of initial involvement is no greater than surrounding normal tissue even if the tissue has high physiologic uptake. No extralymphatic sites of disease  
Nonmeasured L esion  Not applicable  Absent  
Organ E nlargement  Not applicable  Regress to normal  
New L esions  None  None  
Bone M arrow No evidence of FDG -avid disease in marrow  Normal by morphology; if indeterminate, 
IHC negative  
Partial Partial Metabolic R esponse  Partial Remission  
(all of the following)  
Lymph Nodes and 
Extralymphatic S ites Score 4 or 5† with reduced uptake compared with 
baseline and residual mass(es) of any size  ≥ 50% decrease in SPD of up to 6 target 
measurable nodes and extranodal sites  
 At interim, these findings suggest responding 
disease  When a lesion is too small to measure on 
CT, assign 5 mm × 5 mm as the default 
value  
 At end of treatment, these findings indicate residual 
disease  When no longer visible, 0 × 0 mm  
  
For a node > 5 mm × 5 mm, but smaller than 
normal, use actual measurement for 
calculation  
Nonmeasured 
Lesions  Not applicable  Absent/normal, regressed, but no increase  
Organ E nlargement  Not applicable  Spleen must have regressed by > 50% in 
length beyond normal  
New L esions  None  None  
Bone M arrow Residual uptake higher than uptake in  normal 
marrow but reduced compared with baseline (diffuse 
uptake compatible with reactive changes from 
chemotherapy allowed). If there are persistent focal 
changes in the marrow in the context of a nodal 
response, consideration should be given to further 
evaluation with MRI or biopsy or an interval scan . Not applicable  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
74 Response and 
Site PET-CT–Based Response  CT-Based Response  
No Response or 
Stable D isease  No M etabolic R esponse  Stable D isease  
Target N odes/  Nodal 
Masses, Extranodal 
Lesions  Score 4 or 5 with no significant change in FDG 
uptake from baseline at interim or end of treatment  <50% decrease from baseline in SPD of up 
to 6 dominant, measurable nodes and 
extranodal sites; no criteria for progressive 
disease are met  
Nonmeasured 
Lesions  Not applicable  No increase consistent with progression  
Organ E nlargement  Not applicable  No increase consistent with progression  
New L esions  None  None  
Bone M arrow  No change from baseline  Not applicable  
Progressive D isease  Progressive Metabolic D isease Progressive Disease  
requires at least 1 of the following  
Individual Target 
Nodes/Nodal M asses  Score 4 or 5 with an increase in intensity of uptake 
from baseline and/or  PPD progression:  
Extranodal Lesions  New FDG -avid foci consistent with lymphoma at 
interim or end- of-treatment assessment  An individual nod e/lesion must be abnormal 
with:  
- LDi >1.5 cm and  
- Increase by ≥ 50% from PPD nadir 
and 
- An increase in LDi or SDi from nadir  
o 0.5 cm for lesions ≤ 2 cm  
o 1.0 cm for lesions >2 cm 
- In the setting of splenomegaly, the 
splenic length must increase by >50% 
of the extent of its prior increase 
beyond baseline (e.g., a 15 -cm spleen 
must increase to >16 cm). If no prior 
splenomegaly, must increase by at 
least 2 cm from baseline 
- New or recurrent splenomegaly 
Nonmeasured 
Lesions  None  New or clear progression of preexisting 
nonmeasured lesions  
New L esions  New FDG -avid foci consistent with lymphoma rather 
than another etiology (e.g. , infection, inflammation). 
If uncertain regarding etiology of new lesions, biopsy 
or interval scan may be considered. - Regrowth of previously resolved 
lesions  
- A new node >1.5 cm in any axis  
- A new extranodal site >1.0 cm in any 
axis; if <1.0 cm in any axis, its 
presence must be unequivocal and 
must be attributable to lymphoma 
- Assessable disease of any size 
unequivocally attributable to 
lymphoma 
Bone M arrow  New or recurrent FDG -avid foci  New or recurrent involvement  
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
75 Abbreviations:  5PS, 5 -point scale; CT, computed tomography; FDG, fluorodeoxyglucose; IHC, immunohistochemistry; 
LDi, longest transverse diameter of a lesion; MRI, magnetic resonance imaging; PET, positron emission tomography; PPD, 
cross product of the LDi and perpendicular diameter; SDi, shortest axis perpendicular to the LDi; SPD, sum of the product 
of the perpendicular diameters for multiple lesions.  
* A score of 3 in many patients indicates a good prognosis with standard treatment, especially if at the time 
of an interim scan. However, in trials involving PET where de- escalation is investigated, it may be 
preferable to consider a score of 3 as inadequate response (to avoid undertreatment).  
- Measured dominant lesions: Up to six of the largest dominant nodes, nodal masses, and extranodal 
lesions selected to be clearly measurable in two diameters. Nodes should preferably be from disparate 
regions of the body and should include, where applicable, mediastinal and retroperitoneal areas. Non -
nodal lesions include those in solid organs (e .g., liver, spleen, kidneys, lungs), GI involvement, 
cutaneous lesion s, or those noted on palpation.  
- Nonmeasured lesions: Any disease not selected as measured, dominant disease and truly assessable 
disease should be considered not measured. These sites include any nodes, nodal masses, and 
extranodal sites not selected as dominant or measurable or that do not meet the requirements for 
measurability but are still considered abnormal, as well as truly assessable disease, which is any site 
of suspected disease that would be difficult to follow quantitatively with measurement, including pleural 
effusi ons, ascites, bone lesions, leptomeningeal disease, abdominal masses, and other lesions that 
cannot be con firmed and followed by imaging.  
- In Waldeyer's ring or in extranodal sites (e.g. , GI tract, liver, bone marrow), FDG uptake may be greater 
than in the mediastinum with complete metabolic response, but should be no higher than surrounding 
normal physiologic uptake (e.g. , with marrow activation as a result of chemotherapy or myeloid growth 
factors).  
† PET 5 PS: 
1. No uptake above background  
2. Uptake ≤ mediastinum  
3. Uptake >mediastinum but ≤ liver  
4. Uptake moderately >liver  
5. Uptake markedly higher  than liver and/or new lesions  
6. X: new areas of uptake unlikely to be related to lymphoma.  
 
Source: Reprinted with permission. ©  2014 American Society of Clinical Onc ology. All right reserved. Cheson 
BD, Fisher RI, Barrington SF, Cavalli F, et al. Recommendations for Initial Evaluation, Staging and Response 
Assessment of Hodgkin and Non- Hodgkin Lymphoma: the Lugano Classification. Table 3. JCO. 2014 Sep 20; 
32(27):3059- 3068. 
PrECOG Protocol Number: PrE0405 
IND Number: 143290 
Confidential  
Date: 10/ 11/202 1 
 
76 Appendi x VI: Investigator’s Statement  
1. I have carefully read this protocol entitled “Phase II Study of Bendamustine and 
Rituximab plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of 
Age”, Version 5.0 dated 10/11/2021 (Protocol Number PrE0405)  and agree that it 
contains all the necessary information required to conduct the study. I agree to conduct the study as outlined in the protocol.  
2. I agree to conduct this study according to the moral, ethical and scientific principles governing clinical research as set out in the Declaration of Helsinki, the principles of Good Clinical Practice (GCP ) as described in 21 Code of Federal Regulations ( CFR) 
and any applicable local requirements. 
3. I understand that this trial and any subsequent changes to the trial will not be initiated 
without approval of the appropriate Institutional Review Board, and that all administrative requirements of the governin g body of the institution will be complied 
with fully.  
4. Informed written consent will be obtained from all participating patients in accordance with institutional and Food and Drug Administration (FDA)  requirements as specified in 
Title 21, CFR , Part 50.  
5. I understand that my signature on the electronic Case Report Form  (eCRF)  indicates 
that I have carefully reviewed each page and accept full responsibility for the contents 
thereof.  
6. I understand that the information presented in this study protocol is confidential, and I hereby assure that no information based on the conduct of the study will be released 
without prior consent from PrECOG, LLC unless this requirement is superseded by the 
FDA. 
Principal Investigator  (PI): 
PI Name:            
Site Name:            
Signature of PI:           
Date of Signature:    \  \    
    MM  DD  YYYY  
 